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Improving access to the waiting list and kidney transplantation is one of the important 
factors in improving poor outcomes faced by Aboriginal and Torres Strait Islanders 
(Indigenous) Australians with end stage kidney disease (ESKD). This thesis was 
designed to address the following specific aims: 
• To identify the time to placement on the transplant waiting list and time to 
transplantation among Indigenous Australians as compared to non-indigenous 
Australians 
• To examine predictors of placement on the transplant waiting list (and non-
listing) for kidney transplantation utilising existing data from Australia and New 
Zealand Dialysis and Transplant Registry (ANZDATA), which holds waiting list data 
from the National Organ Matching System. 
• To examine relationships between Indigenous patients’ facility haemodialysis 
attendance and the chance of placement on the transplant waiting list, 
transplantation and transplant outcomes.  
• To identify risk factors predictive of good vs poor outcome following 
transplantation among Indigenous recipients, through quantitative studies utilising 
existing ANZDATA Registry data  
Research conducted for this thesis confirmed the increased use of haemodialysis 
along with low numbers of kidney transplantation among Indigenous Australians as 
compared to non-indigenous Australians. Lower numbers of kidney transplant among 
Indigenous Australians were further explored to find whether this related to 
placement on the transplant waiting list and to define the groups who were affected 
by this. A reduction in placement on the transplant waiting list among Indigenous 
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Australians more so among people from remote areas was identified. A significant 
gap in transplantation among Indigenous Australians existed in and after the second 
year on the transplant waiting list. For this and other research conducted in this 
thesis, remoteness was defined by Australian Bureau of Statistics (ABS) remoteness 
categories, by linking ABS postcode of residence concordance data with the 
postcode recorded in the ANZDATA record for the start of RRT. 
Research conducted to explore the association of facility dialysis attendance in 
Indigenous Australians with ESKD and placement on the transplant waiting list and 
transplant outcomes was limited by the low number of outcomes measured. An 
association between placement on the transplant waiting list and transplant 
outcomes was not evident; however, the chance of transplantation was low among 
participants with dialysis attendance ≤2.5 sessions/week.   
Identification of risk factors predictive of good vs poor outcome following 
transplantation among Indigenous recipients was conducted by linkage of hospital-
derived data with data from the Registry. A cohort study comparing pre and post-
transplant hospitalisation among Indigenous kidney transplant recipients of South 
Australia and Northern Territory found increased rates of hospital admissions, 
prolonged hospital stay, and increased rates of infection more so in the first year 
post-transplant. Half of the study participants in our study cohort had delayed graft 
function. Total ischaemia time was more than 16 hours in half of the study 
population. Finally, a retrospective case-control study among Indigenous transplant 
recipients, to explore specific risks factors in the pre-transplant period, showed 
increased rates of hospitalisation to be predictive of early graft loss. No correlation 
was found between other studied factors and graft loss (including patients’ death). 
vi 
 
More studies, including studies to understand pharmacokinetics and 
pharmacodynamics of immunosuppression in Indigenous transplant recipients,  are 
required to look for other factors not examined here. Hospitalisation in the pre-
transplant period needs further exploration and measures identified to reduce these 
events and complications which follow. Policies need to focus in the first year post-
transplant to reduce the burden of hospitalisation. Individually tailored, evidence-
based protocols are required to improve the management of post-transplant 
infections, which may include consideration of broad anti-infective agents. Finding 
ways to reduce ischaemia time and delayed graft function as a result of this factor 
need consideration. 
Development of algorithms and outcome predicting tools taking into account pre-
transplant hospitalisation into the equation may be helpful. Strategies need to be 
developed to increase placement on the transplant waiting list and transplant rates. 
vii 
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“Together we will close the Gap” 1 
 2 
Three things cannot be long hidden 3 
The sun, the moon and the truth 4 
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1. Introduction  1 
 2 
The most severe form of chronic kidney disease (CKD), also known as end stage 3 
kidney disease (ESKD), has a significant impact on the health of an individual and 4 
health-related expenditure of the nation. (1) The burden is even more significant for 5 
Aboriginal and Torres Strait Islander peoples (hereafter respectfully referred to as 6 
Indigenous Australians) in Australia. (2) While Indigenous Australians represent 7 
2.8% of the total Australian population, (3) approximately 10% of all the patients 8 
receiving dialysis for treatment of ESKD are identified as of Indigenous origin. (4, 5)  9 
Dialysis includes haemodialysis (HD) and peritoneal dialysis (PD) and is one of the 10 
treatment modalities used for the treatment of patients with ESKD. Other modalities 11 
of treatment are kidney transplantation or supportive care. Together, dialysis and 12 
kidney transplantation are referred to as kidney replacement therapy (KRT).      13 
Of all these treatment modalities, kidney transplantation is associated with improved 14 
quality of life and is cost-effective when compared to dialysis. This advantage is seen 15 
even after transplantation of marginal quality kidneys (6) and irrespective of dialysis 16 
vintage. (7)  In addition, survival benefits and reduced risk of cardiovascular events 17 
have been described in those receiving kidney transplants. (7) Benefits of 18 
transplantation are independent of the dialysis modality, deceased, or living donors. 19 
(7) It is, therefore, the preferred treatment option for ESKD where medically possible. 20 
(8, 9) It is absolutely vital that every effort is made to increase the number of both 21 
deceased and living donor kidney transplant for all patients with end stage kidney 22 
disease. However, a relatively lower proportion of Indigenous Australians receive 23 




Figure 1.1: Prevalent patients on KRT by ethnicity for the year 2017  2 
Furthermore, it is important to understand that in the process to receive 3 
kidney transplantation, patients must go through several steps (Figure 1.2), 4 
and be wait-listed. (10) Factors that affect the chance of kidney 5 
transplantation can be related to any of these steps, including placement on 6 
the transplant waiting list. In 2003, Cass et al. used Registry data to identify 7 
very low rates of placement on transplant waiting list among Australian 8 
Indigenous patients and proposed that this could be contributing to the low 9 
rates of transplants in this population. (11) However, this work was limited by 10 
the nature of the waiting list data collected by the Registry at that time; there 11 
were inaccuracies, from the fact that it was reported by renal units rather than 12 
from the actual waiting list database, and data lacked key details including 13 




Figure 1.2: Process/ Pathway to receiving a kidney transplant 2 
With the availability of the waiting list database (National Organ Matching System 3 
(NOMS)), which is more accurate and updated than the data examined by Cass et 4 
al.; it was necessary and possible to re-examine the activities on the kidney 5 
transplant waiting list for Indigenous patients. We expected to identify whether 6 
delayed or reduced placement on the transplant waiting list was associated with 7 
these low rates of a kidney transplant seen among Indigenous patients. 8 
Besides, we examined the effect of patient-level information (dialysis attendance) on 9 
the access to the waiting list, kidney transplant and transplant outcomes. 10 
Finally, kidney transplant outcomes (including graft loss and patient death) are 11 
poorer for Indigenous compared to non-indigenous Australians. (12) Even though 12 
previous studies (10, 13-16) have attempted to explore the reasons for the 13 
decreased proportion of kidney transplant and poor transplant outcomes among 14 
Indigenous ESKD patients, these studies were generally based solely on Australia 15 
and New Zealand Dialysis and Transplant (ANZDATA) Registry data. However, this 16 
data lacks granular details at the patient level. We used a detailed examination of 17 
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hospital data to examine factors which affected transplant outcomes. We examined 1 
the effect of remoteness using multivariate regression and shared.  Remoteness was 2 
defined by Australian Bureau of Statistics (ABS) remoteness categories, by linking 3 
ABS postcode of residence concordance data with the postcode recorded in the 4 
ANZDATA record for the start of RRT. 5 
The specific aims of this these are: 6 
• To identify the time to placement on the transplant waiting list and time to 7 
transplantation among Indigenous Australians as compared to non-indigenous 8 
Australians 9 
• To examine predictors of placement on the transplant waiting list (and non-10 
listing) for kidney transplantation utilising existing data from Australia and New 11 
Zealand Dialysis and Transplant Registry (ANZDATA), which holds waiting list data 12 
from the National Organ Matching System. 13 
• To examine relationships between Indigenous patients’ facility haemodialysis 14 
attendance and the chance of placement on the transplant waiting list, 15 
transplantation and transplant outcomes.  16 
• To identify risk factors predictive of good vs poor outcome following 17 
transplantation among Indigenous recipients, through quantitative studies utilising 18 
existing ANZDATA Registry data  19 
Implementation 20 
The projects conducted will identify wherein the process of transplantation, do the 21 
problems lie. These findings will inform which part in the patients’ journey to kidney 22 
transplantation need specific attention and where the changes in policies and 23 
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protocols are to be implemented. One of the studies will prove (or disprove) some of 1 
the factors thought to be associated with poor outcomes of the kidney 2 
transplantation. This finding will provide practitioners with an evidence base and is 3 
likely to affect the decision making for the process of transplantation, thereby 4 
removing assumption induced bias. Finally, identification of these factors and 5 
relationships will inform policymakers and clinicians to formulate strategies to 6 
































Issues around access to transplantation: The known 1 
Factors predicting access to the kidney transplant waiting list and outcomes in 2 
Indigenous Australians may be divided into general factors which affect the overall 3 
health of Indigenous Australians, (17, 18) and kidney transplant specific factors. 4 
General factors affecting the overall health outcomes of Indigenous Australians (17, 5 
18)  6 
Overall, health outcomes among Indigenous Australians are substantially poorer than among 7 
non-indigenous Australians. Life expectancy is 8.6 years less for males and 7.2 years less 8 
for females, (19) age-standardised hospital admission rates are 2.3 times higher, (20) and 9 
Indigenous Australians experience 7.3 times the burden of disease due to chronic kidney 10 
disease. (2)  11 
Several factors contribute to these disparities: 12 
Health system of the country- With health and vitality scores comparable to other member 13 
nations of Organisation for Economic Co-Operation and Development (OECD), Australia 14 
has one of the robust health systems in the world. (21) However, inequitable access 15 
to health services and health outcomes in Indigenous Australians are a major 16 
concern. (2)  17 
The geography of Australia and limited infrastructure in remote areas means limited access 18 
to health care services. (22) Australia’s remote and very remote areas are inhabited 19 
mainly by Indigenous Australians, these areas are thinly populated, and scattered 20 
over a big landmass. (23) According to the population census 2016, only one-third of 21 
Indigenous Australians lived in the major cities. Approximately 38% of Indigenous 22 
Australians lived in the outer-regional, remote and very remote areas. (23) People 23 
living in rural and remote areas face major health challenges. (22, 24) As the 24 
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distance from the major cities increases, levels of illness and mortality rates 1 
increase. (25) The fatal burden of disease, in general, is highest among Indigenous 2 
Australians residing in remote areas, (26) including disease burden due to kidney 3 
and urinary diseases. (2)  4 
These issues of difficult geography and limited infrastructure are reflected in the 5 
prevalence of chronic kidney disease. Very remote areas had more than 6.0 times 6 
the rate of kidney & urinary diseases as compared to Major cities. (27) Hoy et al. 7 
reported 12.8 times more hospitalisations among Indigenous Australians from 8 
remote and very remote areas who had CKD compared to their non-indigenous 9 
counterparts. (28) In 2017-2018, the rate of hospitalisations among people living in 10 
very remote area was twice as high, and 1.3 times higher than for people living in 11 
remote areas. (29) 12 
Indigenous Australians living in rural and remote areas have lower access to health 13 
services such as dentists, doctors, counsellors, health professionals and hospitals. 14 
(17, 29) According to a report by Hussain et al., many remote areas are dependent 15 
on visiting health professionals which leads to lack of continuity of care. (30) Fly in fly 16 
out (or drive in drive out) model of care is prone to frequent interruption in service 17 
delivery due to logistic issues. Flight cancellation and natural disasters are some 18 
examples. (30) Also, Alston M. highlighted an array of reasons associated with 19 
access to primary healthcare (PHC) services in rural Australia, contributing to health 20 
inequalities faced by the people residing in these areas. These include limited 21 
access to doctors and grossly inadequate access to specialists are to name a few. 22 
(22, 29, 31) In a report by Australian Institute of Health and Welfare, limited 23 
availability of specialised service and shortage of health professionals with the 24 
experience to work with complex ESKD patients or kidney transplant recipients was 25 
19 
 
proposed as a possible factor contributing to poor outcome seen in Indigenous 1 
Australians. (32) These issues in access of health services might lead to a delay in 2 
diagnosis and management of the medical conditions.  3 
Similar issues in the context of complex medical conditions such as chronic kidney 4 
disease may exist. Whether they specifically affect onward referral to the kidney 5 
specialists and delay in initiation of specific treatment is not known but likely. Late 6 
referral of patients to the specialists is defined as a situation where kidney 7 
replacement therapy is required within 1-6 months of presentation to the specialists. 8 
Even though the registry-based data does not show a difference in the rate of late 9 
referral to kidney care between Indigenous and non-indigenous Australians, a late 10 
referral might be an issue among Indigenous patients from remote areas as 11 
compared to the major cities. Lim et al. reported a reduction in the occurrence of late 12 
referral in recent times, 25% in 2005 to 18% in 2017, thus still occurring 1 out of 5 13 
Australians with ESKD. (33) Cass et al. reported late referral as one of the many 14 
reasons for the poor outcome of the patients with ESKD. Specifically, the late referral 15 
was associated with increased mortality and decreased access to a kidney 16 
transplant. (34, 35) Moreover, Smart et al. showed early referral to be associated 17 
with improved survival, reduced hospitalisation, early placement of arteriovenous 18 
fistula, better preparation for kidney replacement therapy, and better uptake of 19 
peritoneal dialysis. (36) The ANZDATA Registry reported that the proportion of 20 
arteriovenous fistula at dialysis start to be similar between Indigenous and non-21 
indigenous Australians with ESKD. (4) However, the information on vascular access 22 
for dialysis at the start of KRT only reflects one aspect of comprehensive 23 
management of ESKD patients.  24 
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The problems related to remote residence continue after kidney transplants. 1 
Barraclough et al. showed increased rates of graft loss and patient death in 2 
Indigenous kidney transplant recipients from rural location compared to those from 3 
the urban area. (37) 4 
From the above narrative, it is clear that the geography of Australia is contributory to 5 
the health disadvantage faced by Indigenous Australians residing in these areas. 6 
These issues of poor infrastructure and reduced access to healthcare services are 7 
further complicated by socioeconomic disadvantage, which is higher among 8 
Indigenous Australians living in rural and remote areas than those in major cities. 9 
(38)  10 
Moreover, the poor health outcomes among Indigenous compared to non-indigenous 11 
Australians is also seen in people residing in urban and non-remote areas. 12 
Disparities are reflected in CKD associated hospitalisations, for which the rate ratio 13 
was 2.9 and 3.8 in Indigenous patients from major cities and inner regional areas, 14 
respectively. (28) Also, the age-standardised incidence rates of treated ESKD was 15 
higher among Indigenous Australians from urban areas compared to their non-16 
indigenous counterparts. (39) These observations raise one important question:  17 
‘Are there factors which are common in both non-remote and remote areas which 18 
affect the health outcomes of Indigenous Australians? Are these health system-19 
related or human-related and therefore “systemic racism” or “institutional racism”?’ 20 
Ketchell M. described “systemic racism”, or “institutional racism”, which refers to how 21 
ideas of white superiority are captured in everyday thinking at a systems-level, taking 22 
in the big picture of how society operates, rather than looking at one-on-one 23 
interactions. Systemic racism can stem from education, hiring practices or access, 24 
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including access to health service. (40) Bourke et al. quoted institutional racism to be 1 
a major contributor to the health gap between Indigenous and non-Indigenous 2 
Australians. (41) While the effect of remoteness remains significant, institutional 3 
racism might explain the remaining disparity in health outcomes seen among 4 
Indigenous Australians from the non-remote area. The same authors attributed 47% 5 
of the discrepancy on the health of Indigenous Australians to racism. (41) If such 6 
issues exist, then all Indigenous patients who come in contact with health service are 7 
likely to be affected, including Indigenous patients with ESKD. Despite the 8 
knowledge that institutional racism prevails, there is a paucity of data in this area. 9 
Ben et al. performed a systematic review and meta-analysis on racism and health 10 
service utilisation. They found a significant increase in research in this field in recent 11 
years; however, more than 95% of the studies reviewed were from the United States. 12 
As the saying goes  13 
“You will never find the solution if you do not see the problem”- Gilbert K. Chesterton 14 
Is this why there is a paucity of research on Institutional racism from Australia? Is 15 
this why from 1965 (Convention on the Elimination of All Forms of Racial 16 
Discrimination was opened for signature on 21 December 1965) to 2020 we have 17 
failed to close the health gap between Indigenous and non-indigenous Australians? 18 
(42) The research studies conducted for this thesis have taken into consideration all 19 
factors which were possible to be examined by the quantitative methods. Examining 20 
the effect of institutional racism was beyond the scope of this thesis. However, by 21 
accounting for all other factors possible to be associated with poor outcomes among 22 
Indigenous Australians with ESKD, it may be implied that a significant proportion of 23 
unmeasured residual factor found to contribute to the discrepancy in our studies 24 
might be due to institutional racism.   25 
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Besides, there are other possible risk factors (discussed in the following section) 1 
which may be attributed to the disparity in the health outcomes, including outcomes 2 
related to kidney disease, between Indigenous and non-Indigenous Australians and 3 
may exist in Indigenous Australians from both remote and non-remote areas. 4 
23 
 
Additional possible risk factors for poor kidney health outcomes of Indigenous 1 
Australians 2 
The factors which might play a role in determining the disparity in the health 3 
outcomes may be divided as A. modifiable and B. non-modifiable. These factors 4 
which contribute to the disparity in health outcomes will also be associated with the 5 
outcomes related to kidney disease among Indigenous patients.  6 
A. Modifiable factors include health behaviours, infectious diseases, and 7 
household, social and environmental factors  8 
B. Non-modifiable (or relatively non-modifiable) factors include genetic 9 
predisposition to the disease, gender and age  10 
There is an increased prevalence of comorbidities (such as diabetes, cardiovascular 11 
disease, cerebrovascular disease, and peripheral vascular disease) smoking and 12 
obesity in Indigenous Australians. (39) Furthermore, the prevalence of these factors 13 
is higher in the Indigenous population living in the socially-disadvantaged region, at a 14 
younger age, and the severity of illness is higher than their non-indigenous 15 
counterparts. (39) This increased rate of chronic disease may explain the increased 16 
rate of CKD and ESKD in the Indigenous population. Moreover, obesity, diabetes 17 
and chronic kidney disease are associated with a physical disability and increased 18 
rates of hospitalisation. (43, 44) This adds to increased years of life lost due to 19 
chronic conditions (27, 44) and contributes to more premature death in young 20 
Indigenous Australians. Death rates at age 55-64 are ten times higher when 21 
compared to non-Indigenous Australians. (2)  22 
Also, there are increased rates of childhood infection in this group, such as acute 23 
rheumatic fever, skin infections, and diarrhoeal illness. Geographic and 24 
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environmental factors described before (poor sanitation, decreased access to fresh 1 
foods, overcrowding) also leads to increased rates of infection (17, 27, 39). Frequent 2 
such insults may affect the kidneys (for example by acute kidney injury, post-3 
infectious glomerulonephritis) which can precipitate and aggravate CKD. 4 
Infection also possesses a major issue in Indigenous transplant recipients. 5 
Barraclough et al. (15) reported the excess of infectious deaths in Indigenous 6 
recipients living in urban locations. Rogers et al. (14) examined the transplant 7 
recipients of the NT and found infection to be the most common reason for graft loss 8 
among Indigenous transplant recipients of the region. With 40% of the NT population 9 
residing in remote and very remote areas, Rogers study can be interpreted as that 10 
the infection-related morbidity and mortality is also common in Indigenous transplant 11 
recipients from rural areas. (23)  12 
Barraclough et al. also proposed a variation in immunosuppressive drug disposition 13 
due to racial differences as another explanation of graft loss among Indigenous 14 
transplant recipients. (45) However, this has not been formally examined.  15 
Finally, in a coronial series of seventeen Aboriginal and twenty-four non-Aboriginal 16 
people, investigators found that decreased nephron mass was more common in 17 
Aboriginal Australians. There was a trend of hypertension and low birth weight 18 
among the study participants, and reduced nephron number was associated with 19 
glomerulomegaly. (46, 47) It may be argued that perhaps, a kidney with 20 
glomerulomegaly and hyperfiltration will be less able to withstand further insults from 21 
hypertension, diabetes or infection and thus lead to rapid progression to CKD and 22 
ESKD. Bertram (48) and Hoy (49) identified low birth weight, maternal smoking, and 23 
poor nutrition causing decreased nephron mass as independent factors contributing 24 
25 
 
to the increased prevalence of hypertension, CKD and rapid progression to ESKD. 1 
(48, 49) There are studies underway to identify risk factors which may be genetically 2 
driven. Whether the problems of reduced nephron numbers, glomerulomegaly and 3 
hyperfiltration are genetically linked among Indigenous Australians remains to be 4 
examined. 5 
In the sections and chapters to follow, studies conducted in fulfilment of this thesis 6 
are presented. Through our research, we have attempted to add to a better 7 
understanding of the risk factors focusing more on those that contribute to decreased 8 
access to the best available treatment for Indigenous Australians with ESKD (i.e. 9 
kidney transplantation).  10 
Before delving into the transplant specific access related issues, it is important to 11 
understand the current demography of ESKD among Indigenous Australians. The 12 
enclosed publication (50) provides an overview of KRT in Indigenous Australians 13 
with ESKD compared to non-indigenous Australians; this is followed by a brief 14 
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Abstract. Introduction: Indigenous Aus-
tralians (Aboriginal and Torres Strait Island-
ers, ATSI) make up 3% of the total Australian 
population [1] and comprised ~ 10% of new 
patients beginning renal replacement for end-
stage kidney disease (ESKD) in Australia dur-
ing 2013 [2]. In this study, we examined the 
differences in characteristics, incidence, and 
prevalence of different modalities of dialysis 
and survival between indigenous and nonin-
digenous Australians. Methods: We examined 
outcomes of all adults (aged ≥ 18 years at the 
start of renal replacement therapy (RRT)) in 
the ANZDATA registry who started RRT from 
1st Jan 2003 to 31st Dec 2013 in Australia. Ad-
justed patient survival on dialysis was calcu-
lated using standard techniques. Results: A 
total of 25,528 participants were included, of 
whom 2,447 (9.5%) were indigenous Austra-
lians. Use of facility hemodialysis was more 
common among indigenous people, odds ra-
tio (OR) 1.79 (95% confidence interval (CI), 
1.37, 2.35). Of several interactions between 
indigenous status and other comorbidities, the 
most clinically significant was one with dia-
betes. In fully adjusted models, compared to 
nonindigenous with diabetes; death risk was 
higher for indigenous people with diabetes, 
HR 1.15 (95% CI, 1.06, 1.25). There was no 
difference between the two groups without 
diabetes, HR 0.86 (95% CI, 0.73, 1.05). There 
was no variation in the risks associated with 
ethnicity over year of dialysis start. Conclu-
sion: There are differences in adjusted out-
comes of indigenous Australians compared to 
nonindigenous with ESKD. Interactions sug-
gest that the influence of reported comorbidi-
ties may differ in this group. Further inves-
tigations will be valuable in closing the gap 
and improving health outcome of indigenous 
Australians on RRT.
Introduction
The incidence of treated end-stage kidney 
disease in indigenous Australians (Aborigi-
nal and Torres Strait Islanders) is 10 times 
higher for males and 15 times higher for 
females aged 35 – 64 years than for nonin-
digenous people [2]. Indigenous Australians 
make up 3% of the total Australian popula-
tion [3] and comprise ~ 10% of new patients 
beginning renal replacement for end-stage 
kidney disease (ESKD) [2].
A recent publication [4] showed no im-
provement in the gap in outcomes between 
indigenous and nonindigenous Australians 
with ESKD between 1995 and 2009. In 
2008, the Council of Australian Govern-
ments agreed to address the disadvantage 
faced by indigenous Australians and “close 
the gap” in indigenous people’s health out-
comes, in addition to other targets [5]. We 
extended and updated this comparison of 
indigenous Australians with nonindigenous 
Australians’ outcomes to include the partici-
pants who were treated with dialysis modali-
ties (hemodialysis and peritoneal dialysis but 
not renal transplantation) until the end of the 
year 2013, following implementation of tar-
geted programs at the national level [5].
Methods
Description of cohort and 
inclusion criteria
All adults (≥ 18 years at start of renal re-
placement therapy (RRT)) who started renal 
replacement in Australia during the period 
from 1st Jan 2003 to 31st Dec 2013 were in-
cluded. Indigenous origin is recorded in AN-
ZDATA registry as reported by the renal unit 
on the basis of self-description. 44 records 
were excluded due to inability to link post-
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codes to those recorded by the Australian 
Bureau of Statistics (ABS). The study cohort 
was divided in two categories: indigenous 
Australians (comprising Aboriginal and Tor-




Distribution of RRT modality and all-
cause mortality following start of RRT in 
indigenous and nonindigenous Australians 
were the outcome measures.
Baseline characteristics
Comparisons of comorbidities used Wil-
coxon’s signed rank test and Pearson’s χ2 as 
appropriate.
Remoteness
Remoteness was measured by matching 
the postcode at the start of RRT to remote-
ness concordance tables from the ABS [6]. 
There are five remoteness categories: 1) 
Major cities of Australia; 2) Inner Regional 
Australia; 3) Outer Regional Australia; 4) 
Remote Australia; 5) Very Remote Australia. 
Sensitivity analyses were carried out to as-
sess the association and effect of remoteness 
on the outcome.
Distribution of RRT modality
Comparison was also made between the 
incident modality at the start of RRT and 
prevalence of each modality of RRT at 90 
days, 6 months, and 12 months from the start 
of RRT. The distribution of RRT modality 
was also assessed across the remoteness cat-
egories.
Survival analysis
Patient survival on RRT was calculated 
and compared between the two groups us-
ing Cox regression model adjusting for the 
confounding factors at commencement of 
renal replacement therapy: age, gender, body 
mass index (BMI) category (< 18.5, 18.5 – 
24.9, 25 – 29.9 and > 30 kg/m2), smoking 
status, diabetes, comorbidities (chronic lung 
disease, coronary artery disease, peripheral 
vascular disease, cerebrovascular disease), 
primary kidney disease, late referral (com-
mencing renal replacement therapy within 3 
months of referral to nephrology care), and 
remoteness. Comorbidities reported as “yes” 
and “suspected” were combined as “yes”. To 
investigate the change in outcome over the 
years, year of RRT start was categorized as 
2003 – 2006, 2007 – 2009, and 2010 – 2013.
Given the small number of participants 
in each group, type 1 diabetes was com-
bined with type 2 diabetes, and participants 
in remote categories inner regional, outer 
regional, remote, and very remote Australia 
were grouped together to improve statisti-
cal power. Interactions (between indigenous 
status and each of: age at RRT initiation, 
diabetes, chronic lung disease, and coronary 
artery disease, remoteness) were tested us-
ing Wald tests. Only significant interactions 
were included in the final regression model. 
Survival time was the time a patient started 
on renal replacement therapy until the event 
(death) occurred. Data was censored at the 
end of the survey on 31st December 2013, 
first transplant, and recovery of renal func-
tion or loss to follow up. Odds and hazard ra-
tios were calculated and presented with 95% 
confidence intervals (CI), and a p-value of 
< 0.05 was used as the indicator of statistical 
significance. Statistical analysis used Stata 
version 14.1 (StataCorp LP, College Station, 
TX, USA).
Ethical considerations




There were 25,528 participants, of whom 
9.5% (n = 2,447) were Indigenous Australians. 
There were higher proportion of indigenous 
female participants (n = 1,351, 55.2%) as com-
pared to males (n = 1,096, 44.8%), and co-
morbidities were more common in this group. 
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Mean BMI was similar in indigenous people 
compared to nonindigenous, 28.0 kg/m2 (95% 
CI, 28.4, 29.0) vs. 27.0 kg/m2 (95% CI, 27.6, 
27.8), respectively.
Overall, nonindigenous participants in 
the study were predominantly from Ma-
jor Cities of Australia (72.7%), compared 
to indigenous participants (15.2%). Larger 
proportions of indigenous participants were 
from postcodes corresponding to outer re-
gional Australia (31.4%), remote (22.4%), 
and very remote Australia (21.1%), p-value 
< 0.001(Pearson’s χ2).
Of the RRT modalities, facility hemodialy-
sis was the main modality of RRT; odds ratio 
(OR) for facility HD in indigenous (compared 
with nonindigenous) participants at initiation 
of RRT was 1.79 (95% CI, 1.37, 2.35). This 
OR increased to 2.19 (95% CI, 1.76, 2.74) at 12 
months from RRT start. The point prevalence 
at 12 months since RRT start for the use of 
peritoneal dialysis and home hemodialysis was 
significantly lower among indigenous partici-
pants, OR 0.62 (95% CI, 0.47, 0.81) and 0.42 
(95% CI, 0.21, 0.86), respectively. Remoteness 
was not associated with the use of any of the 
modalities of RRT in the indigenous partici-
pants. In both groups, the proportion of people 
receiving home-based treatment decreased 
over time. Table 1 illustrates the baseline char-
acteristics of participants on hemodialysis and 
peritoneal dialysis at RRT start.
Patient survival
Unadjusted cumulative mortality (Figure 
1) for indigenous participants on dialysis was 
Table 1. Baseline characteristics of participants at entry by hemodialysis (HD) and peritoneal dialysis (PD) (Not included in the table 
are those in the home-HD group and pre-emptive transplant. There were no indigenous participants in the home-HD group at entry, 
and only 3 indigenous participants had received pre-emptive renal transplant).
RRT modality Facility HD* Peritoneal dialysis*
Ethnicity Nonindigenous Indigenous people Nonindigenous Indigenous people
N 16,522 2,048 5,664 396
Age at RRT initiation, median (IQR) 65.0 (54.0, 75.0) 51.0 (43.0, 59.0) 63.0 (51.0, 73.0) 52.0 (44.5, 61.0)
Females 5,974 (36.2%) 1,134 (55.4%) 2,348 (41.5%) 215 (54.3%)
Males 10,548 (63.8%) 914 (44.6%) 3,316 (58.5%) 181 (45.7%)
Body Mass Index (kg/m2)
 < 18.5 (underweight) 523 (3.2%) 71 (3.5%) 183 (3.2%) 10 (2.6%)
 18.5 – 24.9 (normal) 5,435 (33.3%) 606 (30.0%) 2,049 (36.4%) 111 (28.5%)
 25 – 29.9 (overweight) 5,161 (31.6%) 578 (28.7%) 2,005 (35.6%) 131 (33.6%)
  ≥ 30 (obese) 5,200 (31.9%) 762 (37.8%) 1,399 (24.8%) 138 (35.4%)
Comorbidity
 Chronic lung disease 3,005 (18.2%) 401 (19.6%) 774 (13.7%) 68 (17.2%)
 Diabetes (type 1 or type 2) 7,061 (42.7%) 1,669 (81.5%) 2,259 (39.9%) 297 (75.0%)
 Peripheral vascular disease 4,552 (27.6%) 591 (28.9%) 1,213 (21.4%) 127 (32.1%)
 Coronary artery disease 7,322 (44.3%) 869 (42.4%) 1,957 (34.6%) 177 (44.7%)
 Cerebrovascular disease 2,663 (16.1%) 243 (11.9%) 794 (14.0%) 57 (14.4%)
 Late referral 4,353 (26.4%) 616 (30.5%) 732 (13.0%) 71 (18.1%)
Primary renal disease
 GN 3,719 (22.5%) 255 (12.5%) 1,461 (25.8%) 61 (15.4%)
 Polycystic 1,040 (6.3%) 6 (0.3%) 423 (7.5%) 4 (1.0%)
  Reflux 380 (2.3%) 31(1.5%) 190 (3.4%) 7 (1.8%)
 Hypertension 2,632 (15.9%) 146 (7.1%) 857 (15.1%) 28 (7.1%)
 Diabetes 5,105 (30.9%) 1,416 (69.1%) 1,711 (30.2%) 259 (65.4%)
 Other 3,646 (22.1%) 194 (9.5%) 1,022 (18.0%) 37 (9.3%)
Remoteness
 Major cities 12,071 (73.1%) 304 (14.8%) 3,967 (70.0%) 62 (15.7%)
 Inner regional 3,014 (18.2%) 200 (9.8%) 1,053 (18.6%) 39 (9.8%)
 Outer regional 1,260 (7.6%) 529 (25.8%) 536 (9.5%) 118 (29.8%)
 Remote-VRA¶ 150 (0.9%) 1,013 (49.5%) 103 (1.8%) 177 (44.7%)
*RRT modality at entry; ¶Very remote Australia (VRA); participants from remote and very remote Australia combined. RRT = renal re-
placement therapy; IQR = interquartile range; GN = glomerular nephritis.
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lower compared to nonindigenous Austra-
lians (hazard ratio (HR) for death 0.83 (95% 
CI, 0.8, 0.9)), p-value < 0.001. There were 
statistically significant interactions between 
indigenous status and each of the following 
factors: age at RRT initiation, diabetes, coro-
nary artery disease, chronic lung disease, and 
peripheral vascular disease. In general, these 
interactions were not clinically meaningful, 
with the exception of diabetes. There was no 
difference in adjusted survival for indigenous 
and nonindigenous participants without dia-
betes. The risk of death was higher for indig-
enous people with diabetes compared to their 
nonindigenous counterparts, HR 1.15 (95% 
CI, 1.06, 1.25), p-value < 0.05. However, the 
hazard ratio for death for indigenous without 
diabetes compared to their nonindigenous 
counterparts was 0.88 (95% CI, 0.73, 1.05).
Discussion
We have demonstrated a number of im-
portant differences between indigenous and 
nonindigenous people receiving dialysis in 
Australia. Overall, indigenous participants 
were younger but had a substantially high-
er prevalence of comorbidities. Indigenous 
people were predominantly from outside 
major cities of Australia and were treated 
with facility hemodialysis. Despite increased 
efforts to increase the availability of nursing 
and home therapy support outside major cit-
ies [7], disparities in the use of home dialysis 
modalities continue. There are considerably 
greater training and logistic challenges for 
home hemodialysis, particularly in areas 
where water and electricity supplies are not 
reliable [8]. Decreasing use of peritoneal di-
alysis may in addition be due to increased 
rates of peritonitis and technique failure in 
the indigenous group, as has been reported 
previously [9]. Eventually, this may lead to 
technique failure and change in modality [9]. 
While dialysis modality may have an effect 
on survival [10], this was beyond the scope 
of our analysis.
The differences in outcome between in-
digenous and nonindigenous people were 
dependent on diabetes – in those without 
diabetes we did not observe a difference. 
However, among participants with diabetes, 
there was a difference in risk associated with 
indigenous status. We observed no difference 
in the risks associated with ethnicity over 
year of dialysis start in our study. At a prac-
tical level, this extends the findings from a 
previous study [4] of no improvement (over 
2005 – 2009) despite new and ongoing pro-
grams to address indigenous health and ex-
tend service provision.
The standardized death rate according to 
the Australian Bureau of Statistics for indig-
enous people is 9.8 as compared to 5.5 per 
1,000 standard population for nonindigenous 
[1, 6]. Thus, in addition to the factors associ-
ated with dialysis and measured comorbidi-
ties, there may be other unmeasured factors, 
like socioeconomic condition and social dis-
advantage, influencing the difference.
The interactions observed are challeng-
ing to interpret. To improve the statistical 
power, we have restricted the analysis to in-
clude significant interactions and collapsed 
multiple categories (remoteness, diabetes, 
comorbidities, and primary renal disease) to 
binary covariates. The Registry does not col-
lect information about the severity of comor-
bidities; one explanation for the interaction 
observed would be if diabetes were more 
severe or more likely to be associated with 
complications among indigenous people. 
Reporting bias is also a possible factor.
Figure 1. Unadjusted cumulative mortality by 
ethnicity. (However, the risk of death was higher 
for indigenous people with diabetes compared to 
their nonindigenous counterparts. Please refer to 
the text for further details on adjusted HR and sig-
nificant interactions).
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Our study has several strengths, which 
include the large inclusive cohorts of pa-
tients and the consistent adjustment for rel-
evant clinical variables including remote-
ness. There are a number of areas where our 
analyses can be developed. Some are out-
lined above, others include methodological 
developments (for example competing risk 
methodologies to account for differential 
transplant rates), and teasing apart remote-
ness and socioeconomic status. Ongoing 
work will be required to tease out further in-
teractions.
Conclusion
Even though overall survival was seen to 
be improving over more recent years, the ex-
cess risk of death associated with indigenous 
status has not improved. Remoteness contin-
ues to be an important factor in predicting 
death risk in indigenous participants. Indig-
enous origin appears to play a particular role 
in modifying the risk associated with diabe-
tes. This is a complex issue and requires fur-
ther investigations to identify these predic-
tors in closing the gap and improving health 
outcomes of indigenous people with ESKD.
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A brief overview of kidney transplantation in the context of Australia and 1 
Indigenous Australians is presented here.  2 
Although the rate of kidney transplantation has increased in recent years, Indigenous 3 
Australians made up only 3% of transplant recipients in 2017. (51) In 2017, of the 4 
prevalent Indigenous patients, only 13% were treated with kidney transplants (Figure 5 
1.1, page 10). (12) Figure 1.3 shows the prevalent Indigenous transplant patients by 6 
Australian state and territory for the years 2013 to 2017. (12)  7 
 8 
Figure 1.3: Prevalent Indigenous Australian transplant patients 9 
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Similar issues affect other First Nations people and other ethnically disadvantaged 1 
groups. New Zealand (NZ) Māori and Pacific Island people (from countries like 2 
Samoa, Tonga, Niue, Fiji, Tuvalu, Vanuatu, Nauru, the Marshall Islands, and the 3 
Solomon Islands) continue to experience worse socioeconomic and health outcomes 4 
compared with those of other ethnicities. These health inequalities include kidney 5 
disease. (52) Inequities are seen across multiple mortality and morbidity indicators 6 
(e.g. communicable diseases, mental health, and chronic diseases). (53)  7 
End-stage kidney disease in Indigenous population: International context 8 
New Zealand 9 
Being NZ Māori is one of the risk factors for kidney disease on the list provided by 10 
the NZ Ministry of Health. (54) In 2017, 30% of all patients starting KRT in New 11 
Zealand were Māori and an overall prevalence of 57% of the New Zealand dialysis 12 
population. (12) Incident haemodialysis commencement was four-fold higher for 13 
Māori and Pacific people. (12) Among people aged less than 60 years at KRT start, 14 
in 2013, 71% of surviving non-Māori, non-Pacific New Zealanders had received a 15 
kidney transplant by five years compared with 26% of Māori and 25% of Pacific 16 
people. (55) While a constant increase in the numbers of kidney transplant was seen 17 
for Māori and Pacific people in the year 2013 to 2017 (Figure 1.4), an incident pre-18 




Figure 1.4: Prevalent New Zealand Māori patients by modality 2 
 3 
There is increased mortality in the immediate post-transplantation period, and then 4 
the graft survival was comparable to non-Maori, non-Pacific people in the first three 5 
years for the Maori people. Pacific people have an increased rate of graft loss after 6 
18 months of transplantation. (12) Non-related live donor transplants have increased 7 
for this group of people in recent years. 8 
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Canada  1 
Indigenous Australians of Canada include First Nations, Inuit, and Métis people. 2 
They constituted 4.9% of the total population of Canada, according to the 2016 3 
Canadian census. (56) Indigenous Canadians have a disproportionately high burden 4 
of ESKD requiring dialysis and transplantation and are suggested to be driven by the 5 
lack of appropriate pre-dialysis care. (57, 58) Experts suggest the imminent need to 6 
understand the disparities and the reasons for its existence. (59) Underutilisation of 7 
self-care treatment options has been frequently reported among Aboriginal 8 
Canadians. (60-62) Geographic distance to the treatment providing centre has been 9 
thought to play a role in the selection of self-care treatment modality by the 10 
Aboriginal Canadians. (63) One study which involved three study sites and surveyed 11 
99 aboriginal patients reported anxiety and financial issues are perceived as barriers 12 
to peritoneal dialysis by the Aboriginal Canadians. It is suggested that shared 13 
decision making between the treating physician and the patient may help address 14 
this issue. (64)  15 
United States 16 
As per July 2018 census, the Native Americans (American Indians and Alaskan 17 
natives) made up 1.3% of the total population of America. (65)  Historically, the 18 
American Indians and Alaskan natives have the highest rates of kidney disease, (66) 19 
specifically diabetes-related kidney disease. In recent years, with improved diabetes 20 
management among Native Americans, end-stage kidney disease has declined 21 
significantly. (67) The crude transplant rate was more than two-fold higher for the 22 
white Americans, according to the study published in 2009. (13) Transplant rate has 23 
changed in recent years by almost 50%. The rate of transplant in the Native 24 
Americans was 2.8 compared to 3.9 per 100 dialysis patients among White 25 
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Americans in 2017 as per the United States Renal Data System (USRDS) annual 1 
report. (68) 2 
Other parts of the world 3 
Disadvantaged communities, those from low resource, racial and ethnic minorities, 4 
or indigenous backgrounds, suffer from marked increases in the incidence, 5 
prevalence, and complications of CKD worldwide. (69)  Various poverty-related 6 
factors, e.g. infectious diseases secondary to poor sanitation, low birth weight, 7 
inadequate supply of safe water, environmental pollutants, and high concentrations 8 
of disease-transmitting vectors play an important role. 9 
Summary- Putting above discussion and review into perspective for Indigenous 10 
patients with ESKD: 11 
Indigenous Australians face a major disadvantage due to their geographical location. 12 
The unavailability of specialised service and infrastructure such as facilities for 13 
haemodialysis and specialist services required to manage patients with kidney 14 
transplants in remote areas limits management of ESKD patients closer to home. 15 
This leads to displacement, which gives rise to multiple psychosocial issues which 16 
contribute to poorer health outcomes. (70) It would be ideal to manage people from 17 
remote and very remote areas with home dialysis (home haemo- or peritoneal 18 
dialysis) and transplants. However, Lim et al. highlighted factors like logistic and 19 
technical issues, increased rates of peritonitis, technique failure, and peritoneal 20 
dialysis-related mortality in remote areas which make this difficult. (71) Furthermore, 21 
the same authors attributed significant travel distance leading to a lack of appropriate 22 
health services within easy access and when needed and poor attendance for 23 
specialist review, to these discrepancies. (71) A combination of these factors may 24 
explain the high proportions of Indigenous Australians being treated with facility 25 
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haemodialysis, as shown in our study. (50) While a service like that of a mobile 1 
dialysis unit addresses some of these problems, (72) management of ESKD patients 2 
with kidney transplant will be more definitive to keep people in their community. 3 
Compared to dialysis, it is cost-effective and improves the quality of life of the 4 
recipients. In the following section, we will learn about the specific factors affecting 5 
access to the kidney transplant. 6 
  7 
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Factors affecting access to treatment of kidney disease- Kidney transplant specific 1 
factors including waiting list 2 
In previous sections, the general factors that contributed to health disparity faced by 3 
Indigenous Australians were discussed. The factors which are specific to Indigenous 4 
patients receiving dialysis and in particular, relating to access to and outcomes of kidney 5 
transplantation will be discussed here. These factors may be divided into: 6 
Known factors which potentially predict access to the waiting list and kidney transplant 7 
outcomes 8 
Known factors which potentially predict access to a waiting list and kidney transplant 9 
outcomes are outlined here. Cass et al. examined the registry-based data for ESKD 10 
patients from 1993 to 1998 and reported that Indigenous recipients wait longer on 11 
the waiting list. (11) The same authors also reported a decreased rate of 12 
transplantation after placement on the transplant waiting list among Indigenous 13 
Australians. (11) The longer time spent on dialysis potentially increases the morbidity 14 
and mortality, thereby decreasing patients’ likelihood of receiving transplants. (9, 73) 15 
Furthermore, Indigenous recipients have a greater number of human leukocyte 16 
antigen (HLA) mismatches and greater sensitisation. (14, 74, 75) The differences in 17 
HLA distribution between donor and recipient pools might affect waiting times.  18 
Previous studies (14, 37) have explored the effects of comorbidities and remoteness 19 
on kidney transplant outcomes. Compared to their non-indigenous counterparts, 20 
comorbidities are more common among Indigenous Australians before 21 
transplantation. These factors are important determinants of outcome, particularly 22 
patient survival; however, only partially explain the disadvantage faced by 23 
Indigenous Australians. 24 
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Living related kidney transplant could be an alternative to deceased donor 1 
transplantation. However, higher rates of CKD, diabetes and cardiovascular 2 
comorbidities in Indigenous Australians precludes family and friends from the 3 
donation. Previous studies have shown a higher rate of CKD (39) and the risk of 4 
developing severe kidney disease after donation. (76) In these circumstances, 5 
Indigenous Australians have to be highly dependent on the scarce deceased donor 6 
pool.   7 
Proposed factors associated with poor access to the waiting list and kidney 8 
transplant: 9 
As discussed in the previous section (please refer to page 12), to be placed on a 10 
waiting list and be considered for a kidney transplant, one has to go through several 11 
steps shown in Figure 1.2 (please refer to page 12). (10, 77) Difficulties faced at any 12 
of these steps shown in Figure 1.2 can become barriers to access waiting list and 13 
then kidney transplantation, leading to inequalities.  14 
For some of these steps, patients are required to travel to a specialist centre where 15 
there is transplanting facility, and for others, to a regional hospital where a specialist 16 
may be visiting for pre-transplant assessment. This process often requires multiple 17 
and frequent trips to and from the centre. As discussed in chapter 1, Indigenous 18 
Australians from remote and very remote areas frequently face dislocation from their 19 
communities to access dialysis. For them, further travel to a regional centre 20 
frequently to be reviewed by a specialist can be very tiring physically as well as 21 
emotionally. This not only leads to a delay in the process but can increase the 22 
likelihood of people not attending their appointments. It is not just the distance one 23 
has to cover, but the expense related to the travel, accommodation of the 24 
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companion, isolation and having to confront unfamiliar or unwelcoming hospital 1 
environments might often be overwhelming. (78, 79) Similar challenges are faced by 2 
Indigenous Australians accessing other healthcare services besides kidney care, 3 
and also Indigenous people in other parts of the world. Lawrence et al. (80) and 4 
Katzenellenbogen et al. (81) identified fear of hospitals among Indigenous Australians 5 
with acute coronary syndrome. Indigenous Australians in their studies perceived hospitals as 6 
places to go to die or environment being unfriendly, and recognised these as a barrier to 7 
treatment of acute coronary syndrome.  (80, 81) Alexander and Sehgal analysed the 8 
disparities in access to kidney transplant waiting list in Kentucky, Ohio and Indiana. 9 
(82) They concluded that pre-transplant evaluation which often requires multiple 10 
evaluations and frequent visits for sophisticated tests, posed the greatest barrier for 11 
ethnic minorities. 12 
Patient’s chance of being placed on the transplant waiting list is dependent on 13 
whether or not they are referred for pre-transplant assessment and placement on the 14 
transplant waiting list by their treating physicians. Cass et al. (83) and Anderson et 15 
al. (84) conducted studies to investigate physicians’ attitude and its effect on access 16 
to transplantation. These studies (83, 84)  highlighted that practitioners based their 17 
decision-making on patients’ suitability for transplantation and transplant referral on 18 
clinical and behavioural factors. Cass et al. suggested that these factors cluster with 19 
ethnicity and are likely to contribute to poor access to transplantation. (83) Anderson 20 
et al. examined the effect of the treatment compliance, which comprised of frequent 21 
non-attendance in dialysis sessions, clinic reviews, improper medicine utilisation, all 22 
resulting in blood results unacceptable for a patient on dialysis and therefore poor 23 
health and increased hospitalisation. (84) The same authors reported that some of 24 
the Australian Nephrologists who responded to their survey were concerned about 25 
42 
 
the compliance with management among Indigenous Australians while on dialysis. 1 
They concluded that such concern regarding compliance seemed to play some role 2 
in referring these patients for pre-transplant workup. (84) More recently, Barraclough 3 
et al. (37) also confirmed the notion of poor compliance and poor outcome.  4 
From the discussion above, we can synthesise the questions listed below.  5 
• What are the additional factors which predict placement on the transplant 6 
waiting list (and non-listing) on the waitlist for kidney transplantation among 7 
Indigenous Australians 8 
• Are there any associations between compliance with dialysis, hospitalisation 9 
and other markers of engagement with the health system during haemodialysis and 10 
the chance of placement on the transplant waiting list, transplantation and transplant 11 
outcomes?  12 
Chapter 2 presents the publication which examined the effect of traditional 13 
predictors, including comorbidities and remoteness on the rates of placement on the 14 
transplant waiting list and kidney transplantation.  The effect of dialysis attendance 15 
on placement on the transplant waiting list, kidney transplantation and outcomes 16 
among Indigenous patients with ESKD is examined in chapter 3. Chapter 4 includes 17 
two research studies which originated from a cohort of Indigenous kidney transplant 18 
recipients over a decade in an attempt to identify predictors of early graft loss, 19 
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In the process to identify factors influencing the placement on transplant waiting list 1 
among Indigenous Australians with ESKD, the chance of placement on transplant 2 
waiting list information was examined using the most accurate data available. This 3 
section includes the research publication which addressed the following two aims.  4 
1. To identify the time to placement on transplant waiting list and time to 5 
transplantation in Indigenous Australians as compared to the non-indigenous 6 
Australians. 7 
2. To examine predictors of listing (and non-listing) on the waitlist for kidney 8 
transplantation utilising existing data (from the ANZDATA (Australia and New 9 
Zealand Dialysis and Transplant Registry), which holds waitlist data from the 10 
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Disparity of access to kidney transplantation
by Indigenous and non-Indigenous Australians
Namrata Khanal1,2, Paul D Lawton3, Alan Cass3, Stephen P McDonald1,2,4
The known Indigenous Australians with end-stage kidney
disease are less likely to receive a kidney transplant than
non-Indigenous Australians, and those who undergo
transplantation have waited longer for a donor organ.
The new Indigenous patients were less likely than
non-Indigenous patients to be added to the transplantation
waiting list during the first year of renal replacement therapy;
this disparity was not explained by differences in patient- and
disease-related factors. The likelihood of transplantation
during the first year of wait-listing was similar for both groups,
but significantly lower for Indigenous patients in subsequent
years. There are probably unmeasured confounding factors
that influence wait-listing and transplantation rates.
The implications Changes in policy and practice are needed to
improve the access of Indigenous patients to kidney
transplantation.
T he incidence and prevalence of end-stage kidney diseaseare higher among Indigenous than non-IndigenousAustralians, particularly among those aged 15e64
years.1,2 Kidney transplantation is the preferred treatment formost
patients with end-stage kidney disease, especially in this age
group.3,4 Disparities between Indigenous and non-Indigenous
Australians with regard to wait-listing and transplantation have
been identified,5,6 but the relevant studies are relatively old for an
area in which practice has changed substantially. Further, the
waiting list information assessed was drawn from the yearly
Australia and New Zealand Dialysis and Transplant Registry
(ANZDATA) cross-sectional survey of renal units rather than
directly from the waiting list and lacked important details,
including the date of being placed on the waiting list.5
Since 2006, information about kidney transplantation waiting lists
is directly incorporated into the ANZDATA registry, and the
National OrganMatching Systems (NOMS) database provides the
exact date of being added to thewaiting list. Subsequent changes to
waiting list status (eg, active, interim, removal), however, are not
consistently coded. The availability of renal health care has
changed substantially since the most recent published reports5,6
(especially in remote Australia), and the number of deceased
donors has increased substantially. We therefore examined the
likelihood of Indigenous Australians being placed on the waiting
list for transplantation of a kidney from a deceased donor, and the




All patients registered with ANZDATA who started renal
replacement therapy (RRT; dialysis or transplantation) inAustralia
between 28 June 2006 (NOMS database start date) and 31
December 2016 and were 18e60 years old when they commenced
RRT were included. The ANZDATA registry collects data for all
patients with end-stage kidney disease treated long termwith RRT
in Australia. The registry also receives the data fromNOMS for all
registered patients with end-stage kidney disease on the kidney
transplantation waiting list. We analysed a de-identified extract
from these data. The patients were classified according to their
Indigenous status (Indigenous [Aboriginal and Torres Strait
Islander] or non-Indigenous Australians) as reported by the
treating hospital and recorded in ANZDATA.
Patients who underwent pre-emptive kidney transplantation or
multiple organ transplantation were excluded.
Outcomes
The primary outcomes were:
 Time to wait-listing: time between starting RRT and when
the patient was first active on the waiting list. Analyses
were censored for factors that lead to patients being removed
Abstract
Objective: To compare the likelihood of Indigenous and non-
Indigenous Australians being placed on the waiting list for
transplantation of a kidney from a deceased donor; to compare
the subsequent likelihood of transplantation.
Design, setting and participants: Observational cohort study;
analysis of data from the Australia and New Zealand Dialysis
and Transplant (ANZDATA) Registry for patients aged 18e60
years at the start of renal replacement therapy, who
commenced renal replacement therapy in Australia between 28
June 2006 and 31 December 2016.
Main outcome measures: Time to wait-listing; time to kidney
transplantation after wait-listing.
Results: 10 839 patients met the inclusion criteria, of whom
2039 (19%) were Indigenous Australians; 217 Indigenous and
3829 non-Indigenous patients were active on the waiting list at
least once during the study period. The hazard ratio (HR) for
wait-listing (Indigenous v non-Indigenous patients, adjusted for
patient- and disease-related factors) in the first year of renal
replacement therapy varied with age and remoteness (range,
0.11 [95% CI, 0.07e0.15] to 0.36 [95% CI, 0.16e0.56]); in
subsequent years the adjusted HR was 0.90 (95% CI, 0.50e1.6).
The adjusted HR for transplantation during the first year of
wait-listing did not differ significantly from 1.0; for subsequent
years of wait-listing, however, the adjusted HR was 0.40
(95% CI, 0.29e0.55).
Conclusion: Disparities between Indigenous and non-
Indigenous patients with end-stage kidney disease in access to
kidney transplantation are not explained by patient- or disease-
related factors. Changes in policy and practice are needed to
reduce these differences.
1University of Adelaide, Adelaide, SA. 2Central and Northern Adelaide Renal and Transplantation Services, Royal Adelaide Hospital, Adelaide, SA. 3Menzies School of Health
























from the waiting list for transplantation from a deceased
donor (transplantation from living donors, recovery of renal
function, loss to follow-up, death before activation on the
waiting list) and at the end of follow-up (31 December 2016).
 Time to kidney transplantation after wait-listing: the time
from first date of active wait-listing to the date of trans-
plantation, censored for living donor transplantation, death,
and end of follow-up (31 December 2016). The analysis was
not adjusted for intermittent removal of the patient from the
waiting list (“de-activation”) because this information was not
always available.
We examined the association between predictors for wait-listing
and the likelihood of placement on the waiting list, including
Indigenous status, age at the start of RRT, sex, body mass index
(BMI), primary renal disease, comorbid conditions (diabetes, cor-
onary artery disease, cerebrovascular disease, peripheral vascular
disease, chronic lung disease), late referral, year of RRT initiation,
remoteness, and the state where RRT started. Types 1 and 2
diabetes were combined because of low patient numbers. The
likelihood of transplantation and of death for those on the waiting
list was compared by Indigenous status.
Statistical analysis
Frequencies are presented as medians with interquartile ranges
(IQRs). Baseline characteristicswere compared inWilcoxon signed
rank tests and Pearson c2 tests. The frequencies of comorbid con-
ditions in the two groupswere compared using logistic regression.
Time to wait-listing and time from wait-listing to kidney trans-
plantation were assessed in Cox proportional hazards models,
adopting a piecewise approach to maintain the proportional
hazards assumption.7 Themodels were adjusted for age, sex, BMI,
comorbid conditions, primary renal disease, period of RRT
commencement (2006e2009, 2010e2013, 2014e2016), late referral,
state where RRT was started, and remoteness. Remoteness was
defined by Australian Bureau of Statistics (ABS) remoteness
categories, by linking ABS postcode of residence concordance
data8 with the postcode recorded in the ANZDATA record for the
start of RRT. To account for variation in clinical practice that might
affect wait-listing and subsequent transplantation, a shared frailty
model9wasused for the state inwhichRRTstarted. Shared frailty is
a randomcomponent designed to account for variability caused by
unobserved individual-level factors unaccounted for by the other
predictors in themodel. Clinically significant interactions between
Indigenous status and other variables (age, sex, BMI, smoking,
coronary artery disease, chronic lung disease, cerebrovascular
disease, peripheral vascular disease, late referral, primary renal
disease, remoteness) were examined; they were included in the
final multivariate model if statistically significant. P < 0.05 was
deemed significant for main effects and interactions. Statistical
analyses were conducted in Stata 15.0 (StataCorp).
Ethics approval
The study was approved by the human research ethics branch of
the Office of Research Ethics, Compliance and Integrity of the
University of Adelaide (reference, H2016-096).
Results
Patients waiting to be placed on the waiting list:
baseline characteristics
A total of 10 839 patients were eligible for inclusion, of whom 2039
(19%) were Indigenous Australians. The proportions of women
and patients with comorbid conditions (type 2 diabetes, coronary
artery disease, cerebrovascular disease, chronic lung disease,
peripheral vascular disease), and the prevalence of smoking were
higher among Indigenous than non-Indigenous Australians. Most
non-Indigenouspatients (72%) lived in themajor cities ofAustralia,
whereas 38% of Indigenous patients lived in regional areas and
46% in remote or very remote areas (Box 1). The distributions of
comorbid conditions in the Indigenous group were similar for all
remoteness categories, and were similar for Indigenous and
non-Indigenous groups in the same remoteness categories (data
not shown). The median time to wait-listing was longer for
Indigenous than non-Indigenous patients (942 days [IQR,
439e1775 days] v 416 days [IQR, 166e1004 days]) (Box 1).
Likelihood of wait-listing after commencement of renal
replacement therapy
In the unadjusted model, the cumulative incidence of wait-listing
grew more slowly and was less complete for Indigenous patients
(Box 2).
As the hazard ratio (HR) for wait-listing varied with time, we
adopted a piecewise approach to analyses for the first year of RRT
and for subsequent years.7 In the first year of RRT, interactions
between Indigenous status and each of age and remoteness were
statistically significant (Box 3). Accordingly, the adjusted HR
(Indigenous v non-Indigenous patients) during the first year of RRT
varied by age and remoteness. For each combination of remoteness
and age group, Indigenous patients were substantially less likely to
bewait-listed; theHRdeclinedwith age, andwas lower for patients
from remote regions than those from major cities (Box 4).
For subsequent years of RRT, the adjusted HR (Indigenous v non-
Indigenous patients) for being added to the waiting list was 0.90
(95% CI, 0.50e1.6; ie, no significant difference); there were no
statistically significant interactions between Indigenous status and
age or remoteness (data not shown).
Other factors associated with reduced likelihood of wait-listing
(all years) were being female, BMI greater than 30 kg/m2, comor-
bid conditions, smoking, primary renal disease, and late referral
(Box 3).
Characteristics of patients on the kidney
transplantation waiting list
Of the 217 Indigenous patients placedon thewaiting list, 96 (44.2%)
were women, as were 1412 of 3829 non-Indigenous wait-listed
patients (36.9%; P ¼ 0.029). Themedian age at the start of RRTwas
43 years (IQR, 36e51 years) for Indigenous and 48 years (IQR,
39e55 years) for non-Indigenous patients (P < 0.001). The preva-
lence of comorbid conditions was lower among patients placed on
the waiting list than among those who were not (Indigenous and
non-Indigenous combined) (Box 5).
All comorbid conditions (except cerebrovascular disease: odds
ratio [OR], 0.92, 95% CI, 0.40e1.90) were more frequent among
Indigenous than non-Indigenous patients on the waiting list: cur-
rent smoking (OR, 2.40; 95% CI, 1.72e3.35), diabetes mellitus
(types 1 and 2: OR, 5.90; 95% CI, 4.36e7.98), coronary artery dis-
ease (OR, 2.53; 95% CI, 1.77e3.60), chronic lung disease (OR, 1.74;
95% CI, 1.10e2.76), and peripheral vascular disease (OR, 2.20;
95%CI, 1.46e3.32); 38.7%of Indigenous patients and 64.4%of non-
Indigenous patients on the transplantwaiting list had no comorbid
conditions (P < 0.001).
The median time to kidney transplantation after wait-listing was























(IQR, 125e885 days) for non-Indigenous patients (P < 0.029). Of
4046 participants on the waiting list, 2552 (63.1%) received a
deceased donor kidney: 2417 of non-Indigenous (63.1%) and 135
Indigenous patients (62.2%).
After initial placement on the transplant waiting list, 164 patients
died without receiving a deceased donor kidney: 147 non-
Indigenous (3.8%) and 17 Indigenous patients (7.8%). The death
rate from thedate of initial listing to the endof the studyperiodwas
48.3 per 1000 person-years (95% CI, 30.1e77.8 per 1000 person-
years) for the Indigenous group and 22.9 per 1000 person-years
(95% CI, 19.5e27.0 per 1000 person-years) for the non-Indigenous
group. Among those active on the transplant waiting list, the
adjusted HR (Indigenous v non-Indigenous) for death after initial
placement on the waiting list was 0.78 (95% CI, 0.43e1.42).
Likelihood of transplantation among those on the
transplant waiting list
The likelihood of transplantation for Indigenous patients during
the first year of wait-listing was similar to that for non-Indigenous
1 Baseline characteristics of the 10 839 eligible patients included in the study
Baseline characteristics Non-Indigenous Australians Indigenous Australians P
Number of patients 8800 2039
Age at renal replacement therapy initiation (years), median (IQR) 50.0 (41.0e56.0) 49.0 (41.0e54.0) < 0.001
Sex (women) 3298 (37.5%) 1106 (54.2%) < 0.001
Remoteness category < 0.001
Major cities 6369 (72.4%) 297 (14.6%)
Inner regional 1524 (17.3%) 165 (8.1%)
Outer regional 708 (8.0%) 611 (30.0%)
Remote 91 (1.0%) 471 (23.1%)
Very remote 31 (0.4%) 471 (23.1%)
Missing data 77 (0.9%) 24 (1.2%)
Body mass index (kg/m2), median (IQR) 27.4 (23.3e32.9) 28.3 (23.9e33.3) < 0.001
Current smoker (start of renal replacement therapy) 1456 (16.8%) 637 (31.7%) < 0.001
Comorbid conditions
Diabetes 3273 (37.4%) 1624 (79.7%) < 0.001
Coronary artery disease 1980 (22.6%) 730 (36.0%) < 0.001
Peripheral vascular disease 1435 (16.4%) 493 (24.3%) < 0.001
Cerebrovascular disease 754 (8.6%) 212 (10.4%) 0.010
Chronic lung disease 942 (10.8%) 332 (16.4%) < 0.001
None 4206 (48.2%) 260 (12.8%) < 0.001
Late referral 1954 (22.2%) 476 (23.3%) 0.06
Primary renal disease < 0.001
Glomerulonephritis, polycystic, hypertensive, diabetic nephropathy, reflux 7223 (83.0%) 1851 (91.5%)
Other 1479 (17.0%) 171 (8.5%)
Outcome < 0.001
Wait-listed 3829 (43.5%) 217 (10.6%)
Transplantation before wait-listing 20 (0.2%) 0
Death before wait-listing 1604 (18.2%) 644 (31.6%)
Censored 3347 (38.0%) 1178 (57.8%)
Age at wait-listing (years), median (IQR) 49.0 (39.0e56.0) 46.0 (38.0e53.0) 0.004
Time from RRT start to wait-listing (days), median (IQR) 416.0 (166.5e1004.0) 942.0 (439.0e1775.0) < 0.001
IQR ¼ interquartile range. u
2 Unadjusted KaplaneMeier curve for cumulative incidence
























patients, and did not vary over time. For transplantation
in patients aged 40 in the first year of wait-listing, the
adjustedHR (Indigenous v non-Indigenous) for the RRT
period 2006e2009 was 1.4 (95% CI, 0.9e1.9), for
2010e2013 it was 1.8 (95% CI, 1.2e2.4), and for
2014e2016 it was 1.6 (95% CI, 0.6e2.6). There was no
statistically significant interaction between Indigenous
status with period of RRT during the first year of
treatment.
The adjusted HR for transplantation (Indigenous v non-
Indigenous, all periods of RRT) for subsequent years of
wait-listing was 0.4 (95% CI, 0.3e0.6). Other factors that
significantly influenced the probability of kidney trans-
plantation were age (per year: HR, 1.01; 95% CI,
1.00e1.01), sex (men v women: HR, 1.18; 95% CI,
1.09e1.28), BMI ( 30 kg/m2 v < 30 kg/m2: HR, 1.15;
95% CI, 1.05e1.25), and diabetes (HR, 0.85; 95% CI,
0.76e0.94) (Box 6).
Discussion
Despite the increasing availability of nephrology ser-
vices in recent years and national criteria for assessing
patients to be placed on the kidney transplantation
waiting list,10,11 Indigenous Australians undergoing
dialysis are still substantially less likely than non-
Indigenous Australians to be placed on the waiting list.
Multivariate analysis indicated that this disparity was
not explained by differences in kidney disease aetiology,
3 Multivariate Cox model of being placed on the waiting list for kidney transplantation, with frailty shared at state level
Adjusted hazard ratio* (95% CI) P
Indigenous Australian (first year of renal replacement therapy) 0.62 (0.29e1.35) 0.23
Indigenous Australian (subsequent years of renal replacement therapy) 0.90 (0.50e1.62) 0.73
Other covariates
Very remote/remote/regional areas (v major cities) 0.92 (0.85e0.99) 0.019
Interaction: Indigenous status and remote location 0.53 (0.29e0.97) 0.038
Age (per year) 0.99 (0.987e0.993) < 0.001
Interaction: Indigenous status and age 0.98 (0.97e0.99) 0.006
Sex (men v women) 1.18 (1.10e1.26) < 0.001
Body mass index  30 kg/m2 0.61 (0.57e0.66) < 0.001
Primary renal disease† 0.58 (0.53e0.64) < 0.001
Diabetes 0.41 (0.38e0.45) < 0.001
Coronary artery disease 0.66 (0.60e0.73) < 0.001
Chronic lung disease 0.68 (0.60e0.78) < 0.001
Peripheral vascular disease 0.72 (0.64e0.82) < 0.001
Cerebrovascular disease 0.60 (0.51e0.70) < 0.001
Smoker 0.47 (0.43e0.52) < 0.001
Late referral 0.68 (0.62e0.73) < 0.001
Renal replacement therapy, 2010e2013 (v 2006e2009) 1.07 (1.00e1.16) 0.039
Renal replacement therapy, 2014e2016 (v 2006e2009) 1.04 (0.95e1.13) 0.40
* Adjusted for age at the start of renal replacement therapy, sex, body mass index, smoking, diabetes, peripheral vascular disease, coronary artery disease, cerebrovascular
disease, late referral and state where renal replacement therapy was started). † Including category 1: glomerulonephritis, polycystic kidney disease, reflux nephropathy,
hypertensive nephropathy, diabetic nephropathy; category 2: other diseases reported as causing primary renal disease. u
4 Adjusted hazard ratios* (with 95% confidence intervals) for
wait-listing during the first year of renal replacement therapy
(Indigenous v non-Indigenous patients), by age and remoteness
category
* Adjusted for age at the start of renal replacement therapy, sex, body mass index, smoking,
diabetes, peripheral vascular disease, coronary artery disease, cerebrovascular disease, late
referral and state where renal replacement therapy was started). Remote area refers to inner























BMI, comorbid conditions, late referral for RRT, location of treat-
ment, or remoteness, and has not changed with time. The differ-
ence was greater among patients who are older and living in
remote areas. For people on the waiting list, the likelihood of
receiving a transplant is higher in the first year and is similar for
Indigenous and non-Indigenous Australians (43.8% v 31.9%
underwent transplantation in the first year of wait-listing), but is
significantly lower for Indigenous patients in subsequent years.
We analysed more accurate and detailed information on the
waiting list status of patients than earlier studies, including exact
dates of listing5 and more recent data (2006e2016). Our findings
therefore reflect current clinical practice, with nephrology services
well established in more remote areas of central and northern
Australia. It is notable, however, that the unexplained differences
we found are similar to those reported 20 years ago.6
The difference in likelihood of wait-listing was significant for the
first year of RRT and for patients in remote locations, but not
during subsequent years of RRT. This is likely to reflect
geographic factors (living further frommajor centres is a barrier to
testing and clinical review as part of transplantation assess-
ment)12 and factors associated with remoteness not assessed in
our study, such as cultural differences, communication problems,
and different understanding of health.5,13,14 In addition, patients
in remote areas may spend much of their first year on dialysis
dealing with problems of re-location and adjusting to the
demands of treatment rather than assessment for transplantation.
The reduction of these differences over time suggests that this
situation can be improved.
The difference between Indigenous and non-Indigenous patients
in the likelihood of being placed on the transplantationwaiting list
has not changedwith time. Placement on the transplantwaiting list
is the culmination of a series of steps and assessments, including
the patient deciding to pursue this path and the treating clinician
registering this decision, initial medical assessment and referral for
consideration for transplantation, education of the patient about
the merits of transplantation, and assessment by the trans-
plantation unit. We do not know how many patients in our study
were not referred for wait-listing because they decided not to
proceed. However, in a recent analysis of comprehensive in-
terviews of 143 Indigenous patients with end-stage kidney disease
5 Comorbid conditions in patients with end-stage kidney
stage placed or not placed on the waiting list for kidney
transplantation
Comorbid condition Odds ratio* (95% CI)
Current smoker 0.49 (0.45e0.54)
Diabetes (types 1 and 2) 0.32 (0.29e0.35)
Coronary artery disease 0.44 (0.41e0.48)
Cerebrovascular disease 0.41 (0.36e0.48)
Peripheral vascular disease 0.37 (0.33e0.41)
Chronic lung disease 0.48 (0.42e0.54)
CI ¼ confidence interval. * Patients who were wait-listed v patients who were not
wait-listed during the follow-up period, adjusted for age at the start of renal
replacement therapy, sex, and Indigenous status. u
6 Multivariate Cox model of the likelihood of receiving a deceased donor kidney after being placed on the waiting list for
transplantation, with frailty shared at state level
Adjusted hazard ratio* (95% CI) P
Indigenous Australian: first year on waiting list 1.24 (0.89e1.73) 0.20
Indigenous Australian: subsequent years on waiting list 0.40 (0.29e0.55) < 0.001
Other covariates
Sex (men v women) 1.18 (1.09e1.28) < 0.001
Age (per year) 1.01 (1.00e1.01) 0.007
Body mass index  30 kg/m2 1.15 (1.05e1.25) 0.002
Primary renal disease† 1.02 (0.91e1.14) 0.76
Diabetes 0.85 (0.76e0.94) 0.002
Chronic lung disease 0.97 (0.82e1.14) 0.68
Cerebrovascular disease 1.20 (0.99e1.46) 0.07
Coronary artery disease 0.91 (0.80e1.03) 0.14
Peripheral vascular disease 0.99 (0.84e1.16) 0.90
Smoker 1.04 (0.92e1.17) 0.58
Late referral 1.09 (0.99e1.21) 0.09
Very remote/remote/regional areas (v major cities) 0.99 (0.91e1.09) 0.89
Renal replacement therapy, 2010e2013 (v 2006e2009) 1.49 (1.36e1.62) < 0.001
Renal replacement therapy, 2014e2016 (v 2006e2009) 1.46 (1.27e1.67) < 0.001
Interaction: Indigenous status and period of renal replacement therapy
Indigenous Australian: renal replacement therapy, 2010e2013 0.88 (0.56e1.36) 0.56
Indigenous Australian: renal replacement therapy, 2014e2016 0.80 (0.40e1.58) 0.52
* Adjusted for age at the start of renal replacement therapy, sex, body mass index, smoking, diabetes, peripheral vascular disease, coronary artery disease, cerebrovascular
disease, late referral and state where renal replacement therapy was started). † Including category 1: glomerulonephritis, polycystic kidney disease, reflux nephropathy,























from 26 urban, rural, and remote sites across Australia, 90% of
participants expressed strong interest in receiving a transplant.15
In the jurisdictions in Australia where most transplantations for
Indigenous patients are performed (South Australia, Northern
Territory, Western Australia), about 80% of kidneys are allocated
according to waiting time,10 calculated from the start of RRT for
wait-listed patients. Delays in being accepted for the waiting list
consequently lead to patients being near the top of the list at the
time of listing, increasing their likelihood of transplantation soon
after listing. This is reflected in the shorter median time to trans-
plantation after wait-listing and higher rates of transplantation in
the first year after placement on the waiting list, after which the
transplantation rate falls.
Strategies for improving access to and use of renal services by
Indigenous patients have been implemented in recent decades.16
Much more is known about challenges to providing high quality
renal care for Indigenouspatients,5,14 but there havebeen no specific
national policy changes with the aim of improving access to trans-
plantation. At the clinical level, outcomes after transplantation, in
terms of both graft function and patient survival, are considerably
poorer for Indigenous patients,17 particularly for those from remote
areas.18 The potential benefits for patients must be balanced against
these risks when making decisions about treatment.
Limitations
The relatively small number of transplants received by Indigenous
patients during 2006e2016, the limited data on comorbid condi-
tions, and the difficulty of analysing the complex interactions
involved in the effect of remoteness on access to transplantation all
complicate interpretation of our findings. There are probably a
number of other, unmeasured factors that influence wait-listing
and transplantation rates.19 In particular, the ANZDATA registry
does not record active infections or the severity of comorbid con-
ditions, which may have led to our underestimating the effect of
comorbid conditions on wait-listing and access to transplantation.
Further relevant socio-demographic factors — including first
language spoken, education level, health literacy, housing status—
could also affect access to transplantation. Area-level socio-
economic indices for the Indigenous residents of a postcode, rather
than all residents, are not readily available. Further, registry data
do not account for the re-location of many Indigenous Australians
to receive dialysis treatment; that is, their postcode at the start of
RRT may not reflect their community of origin. All these factors
could delay wait-listing.13,14
Conclusion
Indigenous patients with end-stage kidney disease are less likely
than non-Indigenous Australians to be wait-listed for trans-
plantation. This disparitywas particularlymarked for thefirst year
of RRT, and was not explained by the patient- and disease-related
factors assessed. The difference in access early in RRT may reflect
remoteness of Indigenous patients undergoing dialysis, and this
should be a priority area for improving health service delivery.
As the burden of comorbid conditions among Indigenous patients
on the transplantation waiting list was higher than for non-
Indigenous patients, maintaining health and preventing the
development of comorbid conditions should receive more atten-
tion. Further work at policy and practice levels is required to
improve successful kidney transplantation for Indigenous
Australians.
Competing interests: No relevant disclosures.
Received 24 Mar 2018, accepted 4 July 2018.n
ª 2018 AMPCo Pty Ltd. Produced with Elsevier B.V. All rights reserved.
1 Stewart JH, McCredie MR, McDonald SP. The
incidence of treated end-stage renal disease in New
Zealand Maori and Pacific Island people and in
Indigenous Australians. Nephrol Dial Transplant
2004; 19: 678-685.
2 Australian Institute of Health and Welfare. The health
and welfare of Australia’s Aboriginal and Torres Strait
Islander peoples: 2015 (AIHW Cat. No. IHW 147).




3 Wolfe RA, Ashby VB, Milford EL, et al. Comparison of
mortality in all patients on dialysis, patients on dialysis
awaiting transplantation, and recipients of a first
cadaveric transplant. N Engl J Med 1999; 341:
1725-1730.
4 Rabbat CG, Thorpe KE, Russell JD, Churchill DN.
Comparison of mortality risk for dialysis patients and
cadaveric first renal transplant recipients in Ontario,
Canada. J Am Soc Nephrol 2000; 11: 917-922.
5 Cass A, Cunningham J, Snelling P, et al. Renal
transplantation for Indigenous Australians: identifying
the barriers to equitable access. Ethn Health 2003; 8:
111-119.
6 Yeates KE, Cass A, Sequist TD, et al. Indigenous people
in Australia, Canada, New Zealand and the United
States are less likely to receive renal transplantation.
Kidney Int 2009; 76: 659-664.
7 Lindholt JS, Juul S, Fasting H, Henneberg EW. Screening
for abdominal aortic aneurysms: single centre
randomised controlled trial. BMJ 2005; 330: 750.
8 Australian Bureau of Statistics. 1270.0.55.006.
Australian Statistical Geography Standard (ASGS):
correspondences, July 2011: postcode 2012 to
remoteness area 2011. June 2012. http://www.abs.gov.
au/AUSSTATS/abs@.nsf/DetailsPage/1270.0.55.006July
%202011?OpenDocument (viewed July 2018).
9 Sen S, Tom M, Geetha M, Satheesan B. Estimating
unknown heterogeneity in head and neck cancer
survival: a parametric shared frailty approach. Electronic
Journal of Applied Statistical Analysis 2017; 10: 82-92.
10 The Transplantation Society of Australia and New
Zealand. Clinical guidelines for organ transplantation




11 National Health and Medical Research Council. Ethical
guidelines for organ transportation from deceased
donors. Canberra: National Health and Medical Research
Council. Apr 2016. https://www.nhmrc.gov.au/_files_
nhmrc/file/publications/16113_nhmrc_ethical_guidelines_
fot_web_0.pdf (viewed July 2018).
12 Alexander G, Sehgal A. Barriers to cadaveric renal
transplantation among blacks, women, and the poor.
JAMA 1998; 280: 1148-1152.
13 Anderson K, Cunningham J, Devitt J, Cass A. The IMPAKT
study: using qualitative research to explore the impact
of end-stage kidney disease and its treatments on
aboriginal and Torres Strait Islander Australians. Kidney
Int Suppl 2013; 3: 223-226.
14 Cass A, Lowell A, Christie M, et al. Sharing the true
stories: improving communication between Aboriginal




15 Devitt J, Anderson K, Cunningham J, et al. Difficult
conversations: Australian Indigenous patients’
views on kidney transplantation. BMC Nephrol
2017; 18: 310.
16 Cass A, Feyer A, Brown A, et al. Central Australia
Renal Study. Canberra: Australian Department of Health





17 Australia and New Zealand Dialysis and Transplant
Registry. End stage kidney disease in Indigenous peoples
of Australia and Aotearoa/New Zealand. In: ANZDTA




18 Barraclough KA, Grace BS, Lawton P, McDonald SP.
Residential location and kidney transplant outcomes
in indigenous compared with nonindigenous Australians.
Transplantation 2016; 100: 2168-2176.
19 Kotwal S, Webster AC, Cass A, Gallagher M.
Comorbidity recording and predictive power of
comorbidities in the Australia and New Zealand dialysis
and transplant registry compared with administrative


























We identified that Indigenous patients were less likely than non-Indigenous patients 1 
to be added to the transplantation waiting list during the first year of kidney 2 
replacement therapy; this disparity was not completely explained by differences in 3 
patient- and disease-related factors. Given, the significant effect of comorbid 4 
conditions among Indigenous patients on the transplantation waiting list, preventing 5 
the development of comorbidities should also be prioritised. The likelihood of 6 
transplantation during the first year after placement on the transplant waiting list was 7 
similar for both groups but significantly lower for Indigenous patients in subsequent 8 
years. The implications of these findings highlight that changes in policy and practice 9 
are needed to improve the access of Indigenous patients to kidney transplantation. 10 
(77) Whether institutional racism could be among the unmeasured confounders, 11 
needs careful consideration. Our findings were successful in contributing to the 12 








Association between facility haemodialysis attendance and the chance of 6 
placement on the transplant waiting list, and transplant outcomes7 
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From chapter 2, we learnt that the chance of placement on the transplant waiting list 1 
for kidney transplant is lower among Indigenous Australians. Little is known about 2 
the association of dialysis attendance with placement on the transplant waiting list or 3 
transplant outcomes. Previous studies indicate that when dialysis attendance is less 4 
than prescribed, nephrologists’ decisions to refer the patient for transplantation may 5 
be affected. (83) Therefore this study was conducted to examine the third aim of the 6 
thesis, which is described in this chapter. The specific aim of this chapter is: 7 
1. To examine relationships between Indigenous patients’ facility haemodialysis 8 
attendance and the chance of placement on the transplant waiting list, 9 
















The relationship of facility haemodialysis (FHD) attendance in the first two years of 2 
kidney replacement therapy (KRT) initiation with subsequent placement on the 3 
transplant waiting list, and kidney transplant outcome in the NT based Indigenous 4 
Australians with ESKD was examined.   5 
Methods: Existing hospital separation dataset was linked with waiting list information 6 
from the ANZDATA registry. The study examines patients who started KRT from 1st  7 
January 1995 to 31 December 2011. Because, the quality of available data changed 8 
from 28 June 2006, outcome measures and analysis for the two periods have been 9 
differentiated. Three principal outcomes were examined. The first was 10 
transplantation (as an indirect measure for placement on the transplant waiting list) 11 
for all participants. An additional outcome for those who started FHD from 28th June 12 
2006 until 31st December 2011 and were wait-listed by 30th June 2012, was first 13 
active placement on the deceased donor waiting list.  Finally, all-cause graft loss 14 
post-transplantation, including patient death was the outcome measure for patients 15 
who started KRT for the whole period covering 1st January 1995 to 31st December 16 
2011 and were transplanted by 30th June 2012. Dialysis attendance in the first two 17 
years from KRT start was the exposure variable. 18 
Results: The study included 670 people receiving FHD, of whom 301 (44.9%) of 670 19 
on FHD had attendance ≤2.5 sessions/week. Of these, 44 received a deceased 20 
donor kidney transplant, of whom 38 (86.4%) sustained graft loss. Additionally, of 21 
those who commenced KRT from 28th June 2006, 5 were wait-listed. Compared to 22 
those with attendance >2.5 dialysis sessions/week during the study period, 23 
participants with ≤2.5 dialysis sessions/week had the adjusted hazard ratios (HR) of 24 
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0.1 (95% confidence interval (CI), 0.03- 0.24) for a receipt of a kidney transplant and 1 
0.4 (95% CI, 0.1-2.2) for graft loss.  2 
Conclusions: The chance of kidney transplant and placement on the waiting list were 3 
extremely low, and this limited the statistical power of the study. Nonetheless, FHD 4 
attendance ≤2.5 dialysis sessions/week was associated with a reduced likelihood of 5 
transplantation. Strategies to increase placement on the transplant waiting list and 6 
kidney transplantation should be prioritised.  7 






In Chapter 2, it was shown that the likelihood of placement on the transplant waiting 2 
list and kidney transplantation among Indigenous Australians is substantially lower 3 
compared with their non-indigenous counterparts, especially among those living in 4 
remote areas. (77) A range of patient-, provider-, and health system factors have 5 
been postulated to underpin disparities in waitlist access. A critical factor in the 6 
process of transplantation is the initiation of workup and referral by the responsible 7 
nephrologist. While dialysis attendance is not an explicit part of the pre-transplant 8 
assessment process, it is likely to form part of the implicit assessment thereby 9 
affecting nephrologists’ decision to refer the patient for transplant work-up and wait-10 
listing. Because, specific guidelines to identify patients at high risk of non-adherence 11 
post-transplantation do not exist, dialysis attendance is often used as a marker of 12 
compliance to the medical treatment. (86) A national survey conducted in Australia 13 
suggested that when patients attend fewer than the prescribed number of dialysis 14 
sessions, it may affect nephrologists’ decision to refer patients for kidney 15 
transplantation due to concerns about outcomes in the post-transplant period. (83)  16 
Typically, haemodialysis is prescribed three times a week for patients with end-stage 17 
kidney disease (ESKD). Attending fewer than the prescribed number of dialysis 18 
sessions is associated with increased mortality. In studies conducted among United 19 
States dialysis patients, the mortality rate increased by 20-25% and hospitalisation 20 
by 16% in those who missed dialysis once per month. (87, 88) There is a paucity of 21 
data on the effect of dialysis attendance among Australian ESKD patients, including 22 
Indigenous Australians. Previous studies have described decreased attendance at 23 
facility haemodialysis (FHD) among the Northern Territory (NT) based ESKD 24 
patients. (89) However, little is known about the association between dialysis 25 
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attendance and placement on the transplant waiting list, access to and outcomes of 1 
subsequent kidney transplantation. (90) Therefore, this study was conducted to 2 
examine:  3 
1. The relationship between dialysis attendance, placement on the transplant 4 
waiting list and transplantation in NT based Indigenous Australians with 5 
ESKD. 6 
2. The relationship of dialysis attendance with subsequent kidney transplantation 7 
outcomes in NT based Indigenous transplant recipients. 8 
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Methods  1 
Hospital separations data for NT based Indigenous Australians with ESKD for 2 
the period 1st January 1995 to 30th June 2011 was used. These data were 3 
linked to demographic, comorbidity and transplant-related information from 4 
the ANZDATA Registry. As mentioned in chapter two, the registry collects 5 
data of patients with ESKD treated with dialysis and transplantation in 6 
Australia and New Zealand. The registry also receives waiting list information 7 
from the National Organ Matching System (NOMS) database. Data linkage of 8 
hospital separation data and the ANZDATA Registry information was 9 
performed for a previous project by the NT Government Department of 10 
Health’s Health Gains Planning Branch. (89) A de-identified extract was used 11 
for analysis in our study. 12 
All patients on haemodialysis at 90 days after kidney replacement therapy 13 
(KRT) start and wait-listed or received a kidney transplant by 30th June 2012 14 
were included.  15 
Exposure: The primary exposure variable for all outcomes was outpatient 16 
dialysis attendance at FHD during the study period, and in the first two years 17 
from KRT initiation.  18 
Outcome: Deceased donor transplantation (which necessarily requires a 19 
placement on the transplant waiting list and therefore is an indirect measure 20 
for the same) was the outcome measure for participants who were on FHD.  21 
For those who were transplanted, graft loss (loss of graft function requiring 22 
dialysis or patient death) was examined. 23 
Subgroup analysis: For participants who started dialysis from 28th June 2006 24 
(NOMS start date) to 31st December 2011, precise information on the date of 25 
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placement on the transplant waiting list was available. Therefore, additional 1 
analysis was conducted for this group to examine the chance of first active 2 
placement on the waiting list.  3 
These dates were determined by the availability of comprehensive data about 4 
the timing of placement on the transplant waiting list. However, it is also 5 
important to note that the study is part of a PhD thesis which was started in 6 
January 2016. The dataset used for the study with attendance information 7 
until 2011  was, therefore, appropriate when the project was started. This 8 
allowed follow-up of the participants for a minimum period of six months. 9 
Statistical analysis 10 
Wilcoxon's signed-rank test and Pearson's χ2 were used for comparison of 11 
baseline characteristics. Frequency measures were presented as the mean 12 
(standard deviation, SD) or median (interquartile range [IQR]). Comorbidities 13 
between the groups were compared using logistic regression. Cox 14 
proportional hazards model was used to estimate the likelihood of placement 15 
on the transplant waiting list, transplantation, and outcomes of kidney 16 
transplant. Adjusted statistical models included age, gender (male), 17 
comorbidities at the initiation of kidney replacement therapy, and year of 18 
initiation of KRT unless mentioned otherwise. Clinically significant interactions 19 
between ethnicity and other variables were tested separately in the univariate 20 
model. These interactions were included in the final multivariate model if 21 
statistically significant. P-values <0.05 were considered statistically significant. 22 
Stata version 15 (College Station, TX) was used for statistical analysis. 23 
Sensitivity analysis was performed to examine the association of various 24 
categories of dialysis attendance with kidney transplantation, the chance of 25 
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placement on the transplant waiting list, and transplant outcomes. These 1 
categories of dialysis attendance which were examined and compared were:  2 
1. Dialysis attendance of <2 sessions, 2 to 2.5 sessions and ≥2.5 sessions/week  3 
2. Dialysis attendance of <2.5 sessions/ week vs. >2.5 sessions/week 4 
3. Dialysis attendance of <2.75 sessions/ weeks vs. >2.75 session/week 5 
4. Comparison of the lowest quartile with the highest quartile of dialysis 6 
attendance 7 
5. Comparison of the lowest quintile with the highest quintile of dialysis 8 
attendance  9 
No difference in the final outputs for the chance of transplantation, placement 10 
on transplant waiting list or transplant outcome was seen between the 11 
attendance categories listed above. To optimise statistical power, the final 12 
analysis compared to  ≤2.5 and > 2.5 sessions per week (missing fewer than 13 
two dialysis sessions a month) of dialysis attendance. Results comparing 14 
quintiles are also presented in this chapter.  15 
Additional sensitivity analysis examined different periods during which the 16 
dialysis attendance could be measured to derive a clinically meaningful 17 
interpretation. The categories of study period during which dialysis attendance 18 
was measured were: 19 
1. Total dialysis attendance within the study period for included participants. E.g. 20 
Participant ‘A’ started KRT on 1st Jan 1995 and was waitlisted on 30th June 21 
2012. Weekly dialysis attendance in the entire period from 1st January 1995 to 22 
30th June 2012 was used for analysis. 23 
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2. Dialysis attendance in the first two years following KRT start. E.g. In the 1 
example of Participant “A”- weekly dialysis attendance in the period of 1st Jan 2 
1995 to 31st Dec 1997 was used.   3 
3. Dialysis attendance two years before the placement on transplant waiting list 4 
or transplantation. In the same example of participant “A”, weekly dialysis 5 
attendance in the period of 1st July 2010 to 30th June 2012 was used. 6 
4. For those participants with none of these outcomes, weekly dialysis 7 
attendance in the period two year before death or 30th June 2012 was used.  8 
Cox regression analysis using these covariates did not result in a difference in 9 
the overall interpretation of the findings in terms of the association of dialysis 10 
attendance and the chance of placement on the transplant waiting list or 11 
transplant outcome. Among participants who were not wait-listed or 12 
transplanted, the comorbidity burden continued to increase with time spent on 13 
dialysis. Therefore on clinical grounds and the nature of data available, the 14 
final analysis used the dialysis attendance in the first two years since the 15 
initiation of KRT.  16 
The following formula was used to calculate FHD attendance frequency: 17 
            Total number of outpatient dialysis sessions   18 
            Total period during which FHD was performed in the NT in days 19 
Calculation of dialysis attendance did not include time spent in hospital 20 
overnight, interstate, or time receiving peritoneal or home haemodialysis. 21 
Ethical considerations: 22 
This study was approved by the University of Adelaide Human Research 23 
Ethics Committee, and the NT Department of Health and Menzies School of 24 





University. Human Research Ethics approval for Aboriginal and Torres Strait 1 
Islanders was incorporated into the Menzies and the University of Adelaide 2 









There were 890 Indigenous participants who started KRT from 1st January 1995 2 
to 30th June 2011. Of these, 670 received FHD in the first two years following 3 
KRT initiation. Forty-four of 670 participants received a deceased donor 4 
transplant by 30th June 2012. Two hundred sixty-seven participants started KRT 5 
from 28th June 2006 to 31st December 2011. Figure 3.1 shows the distribution of 6 
included participants. 7 
 8 
Figure 3.1: Flowchart showing the distribution of included patients           9 
*Outcome measured for this group was the receipt of a deceased donor 10 
transplant by 30th June 2012 (which necessarily requires a placement on the 11 
transplant waiting list)  12 
¶Total number of patients who started KRT from 1st January 1995 to 31st 13 
December 2011, who were exclusively on facility haemodialysis 90 days of KRT 14 
start ∞ FHD Facility haemodialysis µKRT Kidney replacement therapy 15 
Total Indigenous 
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Baseline characteristics (Table 3.1& 3.2): 1 
The baseline characteristics, according to dialysis attendance, are shown in 2 
Table 3.1. Dialysis attendance was ≤2.5 sessions/ week in 301 (44.9%) 3 
participants. Six of 44 transplanted participants (13.6%) had attendance ≤2.5 4 
sessions/ week. 5 
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All participants Overall Dialysis attendance P-value 
 
≤2.5 sessions/week >2.5 sessions/week  
Number of participants 
in each category 
301 369  
Transplanted or Wait-
listed  
6 (2) 38 (10.3) <0.01 
Age at KRT¶ start, 
median (IQR) 
46.0 (38, 54) 52 (45, 59) <0.01 
Gender (Male) 136 (45.2%) 139 (37.7%) 0.1 
Late Referral 93 (31.4%) 100 (27.3%) 0.3 
Current Smoker 94 (31.2%) 85 (23.0%) <0.05 
Diabetes (present or 
absent) 
224 (74.4%) 298 (80.8%) <0.05 
Coronary artery 
disease 
78 (25.9%) 131 (35.5%) <0.01 
Chronic lung disease 45 (15.0%) 67 (18.2%) 0.3 
Cerebrovascular 
disease 
17 (5.6%) 49 (13.3%) <0.01 
Peripheral vascular 
disease 
53 (17.6%) 104 (28.2%) <0.01 
Table 3.1: Baseline characteristics of all study participants (n=670) according 1 
to their overall dialysis attendance * IQR- Inter-quartile range ¶KRT- Kidney 2 
replacement therapy 3 
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Comparison of the baseline characteristics of participants with dialysis 1 
attendance ≤2.5 sessions/week and >2.5 sessions/week and received kidney 2 
transplantation is shown in Table 3.2.  3 
Table 3.2: Baseline characteristics of the transplanted participants 4 
* IQR- Inter-quartile range ¶ KRT- kidney replacement therapy 5 
 
Transplanted  





N=44 6 38  
Age at KRT¶ start, 
median (IQR*) 
36.5 (31, 44) 45.5 (41, 50) 0.1 
Age at Transplant, 
median (IQR) 
40 (34, 48) 49 (44, 54) 0.1 
Gender (Male) 5 (83%) 22 (58%) 0.2 
Late Referral 5 (83%) 14 (37%) <0.05 
Current Smoker 5 (83%) 12 (32%) <0.05 
Diabetes (present or 
absent) 
2 (33%) 22 (58%) 0.3 
Coronary artery disease 0 (0%) 5 (13%) 0.4 
Chronic lung disease 1 (17%) 1 (3%) 0.1 
Cerebrovascular disease 0 (0%) 4 (11%) 0.4 
Peripheral vascular 
disease 
1 (17%) 5 (13%) 0.8 
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The distribution of the weekly haemodialysis frequency in the first two years of 1 
KRT, among for those who received kidney transplantation, and all 2 
participants is shown in Figure 3.2.  3 
   4 
A       B    5 
Figure 3.2: A. Weekly attendance at Facility Haemodialysis for participants 6 
who were transplanted B. Weekly attendance at Facility Haemodialysis for all 7 
study participants 8 
70 
 
Haemodialysis attendance and the likelihood of transplantation: 1 
Of 670 participants treated with FHD, 44 participants (6.6%) received a 2 
deceased donor kidney transplant by 30th June 2012. Complete information 3 
on dialysis attendance was available for 654 participants. The median time to 4 
transplant from KRT initiation was 3.1 years (Interquartile range (IQR), 2.8-5 
3.5) among those with attendance ≤2.5 sessions/week and 2.9 years (IQR, 6 
2.3-4.0) for participants with attendance >2.5 sessions/week, p-value 0.8. The 7 
majority of participants with dialysis attendance ≤2.5 sessions/week (n=268 8 
out of 301, 89%) were in the lower two quintiles of dialysis attendance. 9 
a. Dialysis attendance in the first two years from the KRT start and 10 
chance of transplantation: 11 
The unadjusted hazard ratio (HR) for transplantation among participants with 12 
≤2.5 sessions/week dialysis attendance in the first two years from the KRT 13 
start was 0.4 (95% CI, 0.2-0.8) when compared to participants with dialysis 14 
attendance >2.5 sessions/week. The adjusted HR for transplantation was 0.2 15 
(95% CI, 0.1-0.5) in participants with dialysis attendance ≤2.5 sessions/ week 16 
in the first two years from the KRT.  17 
No participants with dialysis attendance in the lowest quintile in the first two 18 
years of dialysis attendance received a kidney transplant during the study 19 
period. Compared to participants with dialysis attendance in the highest 20 
quintile in the first two years, the unadjusted HR for transplantation for 21 
participants with attendance in the 2nd lowest quintile was 4.1 (95% CI, 0.8- 22 
22.4) and the adjusted HR was 2.4 (95% CI, 0.4-13.2). 23 
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b. Overall dialysis attendance during the study period and chance of 1 
transplantation: 2 
The unadjusted HR for transplantation among participants with ≤2.5 3 
sessions/week overall dialysis attendance in the study period was 0.3 (95% 4 
CI, 0.1- 0.6) and the adjusted HR was 0.1 (95% CI, 0.03- 0.24).  5 
Finally, compared to participants with the overall dialysis attendance in the 6 
highest quintile, the unadjusted HR for transplantation for participants with 7 
attendance in the 2nd lowest quintile was 0.4 (95% CI, 0.1-1.3), and the 8 
adjusted HR was 0.2 (95% CI, 0.1-0.6).    9 
Haemodialysis attendance and outcome (graft loss or patient death) among 10 
participants on FHD: 11 
Thirty-eight of the 44 FHD participants who received kidney transplants, 12 
experienced graft loss. The overall median graft survival for participants with 13 
dialysis attendance ≤2.5 and >2.5 sessions/ week was 2.9 years.  14 
a. Dialysis attendance in the first two years from the KRT start and 15 
chance of graft loss: 16 
Compared to the participants with dialysis attendance >2.5 sessions/week in 17 
the first two years of KRT, the unadjusted HR for graft loss for participants 18 
with dialysis attendance ≤2.5 sessions/ week was 0.9 (95% CI, 0.4-2.4) and 19 
the adjusted HR was 0.3 (95% CI, 0.1-1.6). Compared to participants with 20 
dialysis attendance in the highest quintile in the first two years of KRT start, 21 
unadjusted HR for graft loss for participants with dialysis attendance in the 22 
second lowest quintile was 5.7 (95% CI, 0.6- 57.8), and the adjusted HR was 23 
9.8 (95% CI, 0.7-140.7). Participants with dialysis attendance in the lowest 24 
quintile did not receive a kidney transplant. 25 
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b. Overall dialysis attendance during the study period and chance of graft 1 
loss: 2 
The unadjusted HR for graft loss for participants with overall dialysis 3 
attendance ≤2.5 sessions/ week in the study period was 1.1 (95% CI, 0.4-2.9) 4 
and the adjusted HR was 0.4 (95% CI, 0.1-2.2).  The unadjusted HR for graft 5 
loss for participants with dialysis attendance in the second lowest quintile in 6 
the overall study period was 1.6 (95% CI, 0.4-6.2) when compared to 7 
participants with attendance in the highest quintile, and the adjusted HR was 8 
1.7 (95% CI, 0.4- 6.9).  9 
Haemodialysis attendance and the likelihood of placement on the transplant 10 
waiting list among participants who started KRT from 28th June 2006 to 31st 11 
December 2011: 12 
Among the participants who started KRT from 28th June 2006 to 31st 13 
December 2011, there were 267 participants on FHD at 90 days from KRT 14 
start. Information on FHD attendance in the first two years from the KRT start 15 
was available for 256 participants, while 253 participants had complete 16 
information on dialysis attendance for the overall study period. Of the 256, 17 
only 5 participants (1.9%) were waitlisted by 30th June 2012. Among these, 3 18 
participants received deceased donor transplants. One hundred and fifty-six 19 
(60.9%) participants had dialysis attendance ≤2.5 sessions/ week in the first 20 
two years from KRT start. Median (IQR) time to placement on the transplant 21 
waiting list was 2.8 years (1.6-3.4) among participants with dialysis 22 
attendance ≤2.5 sessions/ week, and 3.7 years (3.6-3.9) for those with 23 
attendance >2.5 sessions/ week. Due to the small number of participants 24 
achieving the outcome measured, statistical power for further analysis was 25 
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limited. Table 3.3 shows time to placement on the transplant waiting list for 1 
the 5 participants.  2 
 3 






Table 3.3: Time to Placement on the transplant waiting list (in years) for 4 
participants waitlisted by 30th June 2012 5 
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Table 3.4 shows the hazard ratio for transplantation, graft loss and chance of 1 
placement on the transplant waiting list according to the dialysis attendance. 2 
Adjusted Hazard Ratio (95% Confidence Interval) 
 Dialysis 
attendance in 


















quintile in the 














0.2 (95% CI, 
0.07-0.49) 
0.1 (95% CI, 
0.03- 0.24) 
2.4 (95% CI, 
0.42-13.23) 
0.2 (95% CI, 
0.05-0.59) 
Graft loss 0.3 (95% CI, 
0.06-1.62) 
0.4 (95% CI, 
0.09-2.15) 
9.8 (95% CI, 
0.68-140.65) 
1.7 (95% CI, 
0.41- 6.89) 
Placement on the transplant waiting list: 
Total of 5 participants placed on the waiting list, statistical power limited for 
cox regression 
Table 3.4: Hazard ratio (HR) for transplantation, Graft loss and chance of 3 
placement on the transplant waiting list. *KRT kidney replacement therapy 4 




HR is shown according to participants’ dialysis attendance in the first two 1 
years from KRT start, attendance throughout the study period (compared to 2 
dialysis attendance >2.5 sessions/ week) and participants with dialysis 3 
attendance in the second lowest quintile (compared to highest (5th) quintile) in 4 
the first two years from KRT start. Multivariate cox regression adjusted for: 5 
gender, age, comorbidities, smoking status at KRT start, and year of KRT 6 




The most striking finding of this study is the extremely low proportion of 2 
participants on the transplant waiting list. Nonetheless, the likelihood of kidney 3 
transplantation was lower among participants with attendance ≤2.5 sessions/ 4 
week, and those with dialysis attendance in the lowest quintile did not receive 5 
kidney transplantation.  6 
In regards to aim 2 of this study, no association was found between kidney 7 
transplant outcome (graft loss and patient death) and dialysis attendance. The 8 
statistical power of the analysis was limited by a low number of transplantation 9 
among the study participants. 10 
To our knowledge, this is the first study evaluating the relationship between 11 
dialysis attendance with a chance of placement on the transplant waiting list 12 
and kidney transplant outcomes in Indigenous Australians with ESKD. 13 
Furthermore, there is a paucity of data examining treatment adherence using 14 
parameters other than dialysis attendance among Indigenous Australians with 15 
ESKD.  16 
Although the health systems are very different, our findings are similar to the 17 
observations made by Hucker et al. and Denhaerynck et al. (90, 91) Both of 18 
these studies originated outside of Australia, and neither included Indigenous 19 
patients of their regions. Hucker et al. (90) studied the pre-transplantation 20 
adherence behaviours in their dialysis patients and did not find a direct 21 
relationship with post-transplantation adherence to treatment. Denhaerynck et 22 
al. (91) suggested that the determinants of non-adherence in the post-23 
transplant period were not related to dialysis attendance.  24 
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A substantial number of participants on FHD in our study had ≤2.5 sessions/ 1 
week of dialysis attendance, i.e. missing at least two sessions of dialysis per 2 
month. It is not known how this compares to the rest of Australia or 3 
Indigenous Australians from other parts of Australia. Findings similar to our 4 
study were reported by Gray et al. (92) & Chenitz et al. from the US. (93) Gray 5 
et al. reported that haemodialysis patients missed 9.9% of all treatments in 6 
their study, which comprised 40% of United States dialysis population. (92)  7 
Chenitz et al. suggested some determinants of adherence to dialysis in the 8 
Philadelphia area, which included availability of transportation to and from the 9 
FHD centre, lack of motivation to attend dialysis and social factors taking 10 
priority. (93) These determinants may also be relevant to our study 11 
population. However, there are several unique factors about the treatment 12 
location (NT) of this study cohort. Australia’s NT is a large, sparsely populated 13 
area. Many Indigenous patients are required to travel long distances from 14 
home communities to access haemodialysis. Visits home might, therefore 15 
lead to missing FHD sessions. For many Indigenous patients, attendance at 16 
dialysis may conflict with cultural and family obligations. Furthermore, reduced 17 
health literacy, different attitudes to “Western” medicine and the knowledge 18 
about the importance of regular attendance may also be limited, thereby 19 
leading to missing FHD sessions. Health Department sponsored 20 
transportation to and from the dialysis centre might be a solution for 21 
participants living near the centre. This arrangement does not alleviate the 22 
need for participants to relocate closer to a dialysis centre if such facility is not 23 
available locally. Substantial efforts have been made to improve access to 24 
dialysis for people in remote communities, including a visiting dialysis bus 25 
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service and installation of satellite FHD in many remote communities. (94, 95) 1 
Future studies including more recent data will help evaluate the effect of these 2 
interventions. 3 
The lower likelihood of transplantation (and therefore placement on the 4 
transplant waiting list) among Indigenous participants in our study with dialysis 5 
attendance ≤2.5 sessions/ week is consistent with the opinions of the 6 
nephrologists in the national survey conducted in 2007. (83)  Our findings 7 
confirm that the behaviour of nephrologists in practice is consistent with their 8 
stated survey responses. Among the US dialysis patients who missed 9 
dialysis, Gray et al. noted an increased risk for hospitalisation and deaths. 10 
(92) Because this outcome was not examined in our study, it is not known 11 
whether increased hospitalisation or death contributed to low rates of 12 
placement on transplant waiting list and transplantation. 13 
In a review on kidney transplantation among Indigenous Australians with 14 
ESKD, Majoni et al. reported that practitioners concerns about the future 15 
behaviour of dialysis patients based on their dialysis attendance were 16 
controversial, especially given that follow-up and other requirements after 17 
kidney transplantation are very different to dialysis requirements. (96) Once 18 
participants (specifically those from remote locations) return home following 19 
kidney transplant, it would be much easier to plan and arrange travel to the 20 
specialists' appointments every 2-3 months as compared to attending FHD 21 
three times a week. Ongoing attendance at the FHD is perceived to be more 22 
burdensome than the ongoing follow-up after transplant. In the NT, 23 
participants from remote areas face forced relocation to the regional areas 24 
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where dialysis is available, while after receiving transplantation, they can 1 
return to their community. (79, 96)  2 
Based on findings of Improving Access to Kidney Transplant (IMPAKT) study 3 
(10, 97, 98) and by Hughes et al., (79) which included the voice of Indigenous 4 
Australians with ESKD from the NT, transplantation is desirable among this 5 
patient population. Transplantation might provide an opportunity to return to 6 
the community and live with the family, improves emotional wellbeing and 7 
quality of life, and may act as an incentive for participants to look after their 8 
health. (79) The longer time spent on such a complex and strenuous 9 
treatment as haemodialysis may motivate the participants to look after their 10 
health following kidney transplants. The author agrees with the opinion of 11 
Majoni et al. (96) that “patients missing dialysis because of the need to visit 12 
their communities for business issues requiring their presence such as 13 
funerals does not necessarily translate to poor adherence with medications 14 
after renal transplantation”, and this is contrary to the findings of the national 15 
survey (83) which indicated non-compliance as a reason for reduced numbers 16 
on the waiting list.  17 
Because attending fewer than prescribed number of dialysis sessions is 18 
associated with increased mortality, strategies such as measures to increase 19 
awareness about dialysis and problems associated with non-attendance on 20 
dialysis are likely to result in good health while on dialysis. Good health while 21 
on dialysis may lead to an increased chance of placement on transplant 22 
waiting list and transplantation. Also, regular and repeated education about 23 
kidney transplant and what to expect after transplantation is likely to 24 
encourage dialysis patients to remain motivated through the process for 25 
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transplantation. Finally, early initiation of transplant assessment, at chronic 1 
kidney disease stage 4  where possible, is likely to reduce the transplant 2 
opportunities missed due to the increased numbers and severity of 3 
comorbidities as a result of a long duration of haemodialysis.    4 
Implications of the study:  5 
The likelihood of placement on transplant waiting list and transplantation for 6 
our study population was very low. Within the limitation of statistical power, it 7 
is established that ≤2.5 sessions/ week dialysis attendance is not related to 8 
graft loss following kidney transplantation. Therefore this should not be a 9 
determinant reason to not wait-list or not offer kidney transplantation. Rather 10 
than relying on the FHD attendance which was explored in this study, we 11 
recommend that future qualitative studies should focus on patients’ 12 
perspective to understand the barrier to placement on the kidney transplant 13 
waiting list and kidney transplant. Such studies might allow a better 14 
understanding of additional issues around the reduced number of placement 15 
on the transplant waiting list and kidney transplants. Also, strategies to 16 
improve placement on transplant waiting list such as availability of pre-17 
transplant work-up closer to the communities should be considered. 18 
Similarly, evaluation of existing programs such as those utilising the role of 19 
Indigenous kidney transplant recipients in mentoring their peers receiving 20 
haemodialysis is likely to be helpful. Peers who have received transplantation 21 
can explain the processes and procedures in ways understandable and more 22 
relevant to the patients. Utilisation of such resources may then positively 23 
affect the chance of placement on the transplant waiting list and kidney 24 
transplantation.  25 
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There are limitations to this study. In addition to issues related to 1 
observational and retrospective nature of the data, small sample size limits 2 
the statistical power of the study. This is a problem inherent to our study 3 
population despite the inclusion of all Indigenous Australians with ESKD 4 
during the study period. The most critical issue is the very low rate of 5 
placement on the waitlist, and therefore very low numbers of endpoints. 6 
Finally, a key implication arising from this study is the need for further data.  7 
Our analysis used existing data. Our study described in chapter 2 indicated 8 
that the problems with placement on the transplant waiting list/transplantation 9 
facing Indigenous Australians with ESKD are not geographically restricted and 10 
are ongoing. Our study highlights the need for an updated analysis of current 11 
data to resolve the statistical issues that impact current practice.  12 
 13 
Conclusion: 14 
In the Northern Territory study cohort, rates of placement on the kidney 15 
transplant waiting list among Indigenous Australians with ESKD receiving 16 
FHD are low. FHD attendance ≤2.5 sessions/ week was associated with a 17 
reduced chance of kidney transplantation. In the study cohort, we did not find 18 
differences in kidney transplantation outcomes between different FHD 19 









Identification of risk factors predictive of good vs poor outcome following 
transplantation among Indigenous transplant recipients
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Earlier in chapter 2, we discussed the known factors which are associated with graft 1 
and patient survival. Previous studies (11, 14, 75) have utilised information drawn 2 
from the Registry data. The registry data is limited in providing information on 3 
specific clinical and administrative factors at patient and hospital levels. The 4 
association between reasons for hospital admission pre-transplant, types of infection 5 
in cases of infection-related admissions, the severity of illness,  length of hospital 6 
stay, discharge destination, the severity of comorbidities, and patient or graft survival 7 
are not known. Also, the association of types of immunosuppression, rejection and 8 
its management in the post-transplant period and patient or graft survival are 9 
unknown for Indigenous kidney transplant recipients.  10 
Therefore, in following two studies we plan to investigate these associations in 11 
Indigenous kidney transplant recipients, how they compare in the pre-transplant and 12 
the post-transplant period and how they compare between those who have a 13 
functioning kidney transplant and those for whom their kidney transplant is not 14 
working. A cohort study was conducted to compare the factors in the pre and post-15 
transplant period, and a case-control study has been chosen as the best way to 16 
efficiently gather more detailed information about an unusual event comparing those 17 
who have a functioning kidney transplant and those for whom their kidney transplant 18 
is not working. Given graft loss is an outcome with a long latency period; the case-19 
control design allows exploration of risk factors within a logistically feasible number 20 





4.1 Pre and post-transplant hospitalisation among Aboriginal and Torres Strait 1 
Islander kidney transplant recipients 2 
Synopsis: 3 
Kidney transplant outcomes among Aboriginal and Torres Strait Island  (Indigenous) 4 
Australians are poorer than their non-indigenous counterparts(12). This reflects an 5 
increased frequency of post-transplant infection, rejection and higher mortality rates 6 
among this group (14, 15). However, there is little information about hospitalisation 7 
rates and causes, a key marker of morbidity, in this group. In this study, we 8 
examined the hospital experiences of Indigenous kidney transplant recipients of 9 
South Australia (SA) and the Northern Territory (NT) in their two years pre-transplant 10 
and two years post-transplant period.  11 
Objective: To compare the morbidity burden of infection and hospitalisation in the pre 12 
and post-transplant period among Aboriginal and Torres Strait Islander (Indigenous) 13 
kidney transplant recipients who underwent transplantation in South Australia (SA). 14 
Design: A descriptive, retrospective cohort study was conducted. Data from hospital-15 
based medical records, for Indigenous kidney transplant recipients from 1st January 16 
2005 to 31st December 2015 was analysed. 17 
Participants and Setting; All Indigenous kidney transplant recipients from all hospitals 18 
in SA and the Northern Territory (NT)  19 
Main outcome measure: Rates of hospitalisation in the pre- and post-transplant 20 
period. Encounters for maintenance haemodialysis were excluded. Hospital 21 
admission rates including and excluding day admission for kidney biopsy or ureteric 22 





Result: Eighty-nine transplants were performed among 88 recipients. The rate of 1 
hospital admission, excluding maintenance haemodialysis, was 2·4 (95% confidence 2 
interval (CI), 2·2, 2·7) per person-year in the pre-transplant period, 3·4 (95% CI, 3·0-3 
3·8) in the first and 1·4 (95% CI, 1·1-1·6) per person-year in the second year post-4 
transplantation. Rate of admissions with infection was higher in the post-transplant 5 
than the pre-transplant period, 1·6 (95% CI 1·4-1·8) vs. 0·6 (95% CI, 0·5-0·8) per 6 
person-year. The mean overall hospital days were longer in the two-year post-7 
transplant compared with the pre-transplant period.  8 
Conclusion: Length of hospital stay, rates of hospitalisation, and rate of admission 9 
with infection were high in the first year after transplantation, falling in the second 10 
year. A multifaceted approach to reduce the early excess morbidity burden after 11 
transplantation for this group is critical, including exploration of new clinical 12 
processes and identification of targeted areas for further study.13 
Pre and post-transplant hospitalisation among Aboriginal 
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1 Pre and post-transplant hospitalisation among Aboriginal and Torres Strait Islander 
2 kidney transplant recipients
3 Abstract:
4 Objective: To compare the morbidity burden of infection and hospitalisation in pre 
5 and post-transplant period among Aboriginal and Torres Strait Islander  (Indigenous) 
6 kidney transplant recipients who underwent transplantation in South Australia (SA).
7 Design: A descriptive, retrospective cohort study was conducted. Hospital-based 
8 medical records for Indigenous transplant recipients from 1st January 2005 to 31st 
9 December 2015 was analysed.
10 Setting: All Indigenous kidney transplant recipients from all hospitals in SA and the 
11 Northern Territory (NT) 
12 Outcome measure: Rates of hospitalisation in the pre- and post-transplant period 
13 Result: Of the 89 transplants among 88 recipients, 43 (49%) were from remote 
14 areas, and the majority were from the NT (88%). The rate of hospital admission, 
15 excluding maintenance haemodialysis, was  2·4 (95% confidence interval (CI), 2·2, 
16 2·7) per person-year in the pre-transplant period, 3·4 (95% CI,3·0-3·8) in the first 
17 and 1·4 (95% CI,1·1-1·6) per person-year in the second year post-transplantation. 
18 Rate of admissions with infection was higher in the post-transplant than the pre-
19 transplant period, 1·6 (95% CI 1·4-1·8) vs. 0·6 (95% CI, 0·5-0·8) per person-year. 
20 Conclusion: Almost half of the study participants were from remote areas, and the 
21 majority were from the NT. Length of hospital stay, rates of hospitalisation, and rate 
22 of admission with infection was high in the first-year after transplantation, falling in 






























































1 the second-year. The number of transplant recipients living in remote areas is 
2 steadily increasing, and their care is becoming an important facet of remote practice. 
3
4 Keywords:  chronic kidney disease (CKD), clinical epidemiology, clinical nephrology, 
5 registries, transplantation






























































1 What is already known on this subject: 
2  Improving kidney transplantation outcomes for Indigenous recipients is an 
3 agreed national priority. 
4  Indigenous transplant recipients from the remote areas have the highest 
5 chance of graft loss. Previous registry studies have shown higher mortality 
6 rates and increased graft loss as a result of post-transplant infection and 
7 rejection among this group. 
8 What does this study add: 
9  The utilisation of hospital-level data showed increased hospitalisation rates in 
10 the post-transplant period with prolonged length of stay, increased need for 
11 ICU admissions and higher rates of admission where an infection was 
12 documented. 
13  The burden of hospitalisation was greater in the first year post-transplantation 
14 compared to the second year indicating that changes in strategies and 
15 protocols should focus in the first year post-transplantation. 
16  Our findings indicate these factors are likely predictors of poor outcome for 
17 Indigenous kidney transplant recipients, including those from remote and very 
18 remote areas. Furthermore, it provides areas to be addressed to improve the 
19 post-transplant outcome for Indigenous recipients.































































2 Except for dialysis outcomes, which are comparable between the Indigenous and 
3 non-Indigenous end stage kidney disease patients, Indigenous Australians have 
4 worse outcomes for kidney transplantation. (1, 2) The disparity is more pronounced 
5 among the Indigenous transplant recipients from rural areas as compared to the 
6 Indigenous recipients from the major cities and inner regional areas. (2) Higher rates 
7 of deaths due to infection may explain decreased rates of graft and patient survival in 
8 Indigenous kidney transplant recipients; with the risk highest from 6 to 24 months 
9 post-transplantation. (3) Previous studies using registry data have focused on graft 
10 function and mortality. (2-5) 
11 Registry data is broad, but it lacks depth and hospital-level details. There is little 
12 information about hospitalisation rates and reasons for hospitalisation, which are key 
13 markers of morbidity for Indigenous Australians. In this study, we explored this issue 
14 in detail using hospital-level data about Indigenous kidney transplant recipients from 
15 South Australia (SA) and the Northern Territory (NT) in their two years before and 
16 after transplantation. 
17 Methods
18 All Indigenous kidney transplant recipients who received a kidney transplant through 
19 the SA/NT kidney transplant service from 1 January 2005 to 31 December 2015 
20 were included. This service is based in SA and provides kidney transplantation to 
21 individuals throughout SA and NT. This includes end stage kidney disease (ESKD) 
22 patients from all remoteness categories referred from the Royal Darwin Hospital 
23 Alice Springs Hospital Central and Northern Adelaide Renal and Transplant Services 
24 and the Flinders Medical Centre. Data on patient admissions were taken from 
25 hospital records. This included the frequency and duration of hospital admissions, 
26 reason for each admission as documented in the discharge summary or the progress 
27 notes when the summary was missing, laboratory and radiologic investigations, date 
28 of discharge following each admission, pre-transplant investigation results, transplant 
29 events, transplant kidney biopsy results and drug levels. Information was obtained 
30 for the two years pre-transplant, peri-operative and post-transplant periods for the 
31 participants included. The ‘index admission’ for transplant surgery (‘peri-operative 
32 period’) was defined as the period from the day that the participant was admitted to 






























































1 the hospital for the transplant operation until discharge for the first time post-
2 transplant surgery. Hospital-based electronic and hard copies of patients’ medical 
3 records were reviewed. Where applicable, information was cross-checked with data 
4 on Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). Data 
5 from the registry were utilised where data were missing from the hospital records.
6 The hospital admission rate was defined as the number of hospital admissions per 
7 person-year. Patients were followed-up on for two years post-transplant or death, 
8 whichever occurred first-only hospital encounters for maintenance haemodialysis in 
9 both pre- and post-transplant periods were excluded. An infection episode was 
10 defined as a hospital admission in which any infection was documented during the 
11 admission by either the results of the investigation or if the diagnosis given by the 
12 treating team was labelled as infection-related.
13 The coronary angiogram results were categorised based on the cardiologist’s 
14 interpretation provided in the report. The results were categorised as abnormal if the 
15 cardiologist’s report mentioned the involvement of any number of coronary arteries 
16 and reported other than a minor disease. Delayed graft function was defined as 
17 requiring dialysis in the first-week post-transplantation. 
18 Remoteness was determined using the Australian Bureau of Statistics (ABS) 
19 categories based on the postcode of residence. (6) The time taken to return to the 
20 referring hospital was calculated as the time from transplant to the first encounter at 
21 the referring hospital (where the referring hospital was different from the 
22 transplanting hospital). The date of return to the remote community was considered 
23 either the actual date documented when the participant returned to the community 
24 with a functioning transplant or the date of attendance of the last clinic visit when an 
25 intention to return to the community was noted and was accompanied by indirect 
26 evidence of community residence (e.g., a blood test taken in the community or 
27 presentation to the community hospital). 
28 Frequencies and proportions were calculated for each variable. Data were analysed 
29 using Stata 15 (College Station, TX).
30 This study was approved by the Office of Research Ethics, Compliance and Integrity 
31 Research Services, the University of Adelaide; Human Research Ethics Committee 






























































1 of the Northern Territory Department of Health and Menzies School of Health 
2 Research; Central Australian Human Research Ethics Committee; Royal Adelaide 
3 Hospital Central Adelaide Local Health Network Human Research Ethics Committee; 
4 Flinders Medical Centre South Adelaide Local Health Network Human Research 
5 Ethics Committee; and the Aboriginal Human Research Ethics Committee, SA.
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1 Results: Cohort characteristics 
2 A total of 88 participants met the inclusion criteria, their baseline characteristics and 
3 those of the transplants are presented in Table 1a and 1b, respectively. Participants 
4 from the NT made up the majority of the study population. Forty-three (49%) of the 
5 transplant recipients were from the remote areas (ABS ‘Remote and Very Remote’ 
6 classifications), and the majority 38 (88%) were from the NT. The proportion of 
7 participants from remote areas was higher in the NT group than the SA group (76% 
8 vs 11%). There were more male participants than female participants. The median 
9 age at the start of renal replacement therapy (RRT) was 43·5 years (Interquartile 
10 ratio [IQR], 35, 49) and the median age at the time of transplantation was 47 years 
11 (IQR, 41, 55). Twelve deaths (13·5%) occurred within two years of transplantation, of 
12 which 7 (58·3%) were in the first year post-transplant, including three deaths during 
13 the index admission. 
14 Of 277 post-transplant biopsies performed (excluding 80 implantation biopsies) on 
15 89 transplants, 95 (34·3%) had histopathologically established acute rejection, 
16 including both cellular and vascular rejection. The indication for 67/277 (24·2%) of 
17 biopsies was recorded as ‘protocol’. Of the protocol biopsies, six (8·9%) biopsies 
18 revealed some form of acute rejection. Information on specific treatment was 
19 available for 76 (80%) of the 95 biopsies performed for rejection episodes; of these 
20 51 (67·1%) had an escalation of immunosuppression, and 19 (25%) received anti-
21 thymocyte globulin alone or in combination with other changes in maintenance 
22 immunosuppression for the treatment of rejection. For 20% of episodes, information 
23 on treatment for rejection was missing in both the hospital file and the registry 
24 database. 






























































1 The two-year pre-transplant period
2 A total of 431 hospital admissions were recorded for 80 participants during the two-
3 year pre-transplantation period. The remaining eight participants had no hospital 
4 admissions during this period. The hospital admission rate one to two years pre-
5 transplant was similar to the year immediately pre-transplant (2·3 per person-year 
6 (95% CI, 2·0-2·7) vs. 2·5 per person-year (95% CI, 2·2-2·9)). The median number 
7 (IQR) of days spent in the hospital in the two-years pre-transplant period was 16·5 
8 (7·0-35·5) days per person.
9 Index admission for transplant surgery(peri-operative period) 
10 There were 89 kidney transplant operations performed during the study period 
11 (Table 2). One participant received two kidneys within the study period. Of the 89 
12 transplants, eight (9·0%) were second grafts. Table 2 shows the details of the 
13 admission episode for the transplant operations; the median length of stay was nine 
14 (IQR 7, 12) days, with 11% requiring admission to the intensive care unit during 
15 admission for transplant surgery, with a median length of stay in the intensive care 
16 unit of one day (IQR, 1, 4). The median total ischaemia time was 16·5 hr (IQR 13–
17 21), and delayed graft function requiring dialysis occurred in 52% of transplants.
18 Post-transplant period
19 There were 779 hospital admission episodes in the two-year post-transplant period. 
20 The majority (53·2%) of the hospital admissions in the post-transplant period were 
21 day admissions for graft biopsy or ureteric stent removal. Excluding day admissions, 
22 the hospital admission rate in the two years post-transplant was 2·4 per-person year 
23 (95% CI, 2·2-2·7); 3·4 (95% CI, 3·0-3·8) per person-year in the first 12 months after 
24 transplantation falling to 1·4 (95% CI, 1·1-1·6) per person-year in the second year. 
25 Thirty-six episodes (5.6%) of the hospital encounters were recorded as the 
26 presentation at a rural hospital; details of these encounters were unavailable. Figure 
27 1 shows the mean length of stay in pre and post-transplant period and the first and 
28 second-year post-transplantation., while Table 3 shows the overall hospital 
29 admission data for the pre and post-transplant period.
30 Figure 2 shows the time taken in days for the participants to return to the referring 
31 hospital not counting for those referred from within the transplanting hospital. The 






























































1 median time to return to the referring hospital was 38 days (IQR, 30–49). The 
2 majority of patients returned 21–56 days post-transplantation. Data on the return of 
3 participants from areas other than major cities to their community residence (n = 70) 
4 were only available for 39 (55·7%) of the study participants. Of these 39, two (5·1%) 
5 returned within four weeks of transplant surgery, 12 (30·8%) returned within four to 
6 eight weeks, and 25 (64·1%) returned after more than eight weeks.
7 Details of admissions in which infection was documented 
8 The rate of admissions in which infection was documented was higher in the post-
9 transplant period at 1·6 (95% CI 1·4-1·8) vs. 0·6 (95% CI 0·5-0·8) per person-year in 
10 the pre-transplant period. The rate of admissions in which infection was documented 
11 was higher in the first-year post-transplant period compared with the second-year 
12 post-transplant period, with 2·3 (95% CI, 2·0-2·7) vs. 0·9 (95% CI, 0·7-1·2) episodes 
13 per person-year. Figure 3 and the Appendix table i provide details on admissions in 
14 which infection was documented in the pre- and post-transplant period.
15 Of the 69 participants in whom infection was documented during at least one of the 
16 post-transplant hospital admissions, the biopsy-proven rejection was documented in 
17 37 (53·6%) participants, and an escalation of immunosuppression was recorded in 
18 33 (47·8%) participants. Data on the treatment of rejection were not available for four 
19 (10·8%) of the 37 participants with biopsy-proven rejection. Of the 37 participants 
20 with biopsy-proven rejection, 31 (83·8%) had an escalation of immunosuppression 
21 before admission episode in which infection was documented.
22 Out of 274 admission episodes in which infection was documented, 105 (38·3%) 
23 episodes happened after an escalation of immunosuppression for biopsy-proven 
24 rejection. Seventy (66·7%) of the 105 episodes occurred in the first year post-
25 transplantation. The rate of hospital admission episodes in which infection was 
26 documented with an escalation of immunosuppression was 0·5 (95% CI, 0·3-0·7) per 
27 person-year.  This was similar to the admission rate among patients without an 
28 escalation of immunosuppression, and the incidence rate ratio was 1·1 (95% CI, 0·7-
29 1·8)). Appendix Table ii lists the types of infection documented during admission 
30 after an escalation of immunosuppression.






























































1 The vast majority of participants were cytomegalovirus (CMV) immunoglobulin (Ig) 
2 G, Epstein–Barr virus (EBV) IgG and Varicella zoster virus (VZV) IgG-positive pre-
3 transplant. A positive blood CMV polychromatic chain reaction PCR result was 
4 recorded in 42 (47·2%) participants on at least one occasion in the two-year post-
5 transplant period. Similarly, 19 (21·4%) had at least one documented positive blood 
6 BK virus PCR result.
7 Pre-transplant latent tuberculosis (TB) was detected in 13 (14·6%) of the 89 
8 transplants. For participants at low risk for TB (n=55), screening for TB was not 
9 performed. All cases of latent TB completed treatment with isoniazid for nine months 
10 pre-transplant. There were no cases of TB two years post-transplantation in this 
11 group. Pre-transplant screening test results are presented in Appendix Table iii.































































2 Kidney transplantation offers an advantage in survival, quality of life and cost 
3 compared with dialysis across a variety of groups. (7-9) However, graft loss is highest 
4 among the Indigenous transplant recipients from the remote areas. (2) Improving the 
5 rate of kidney transplantation and graft and patient survival among Indigenous end-
6 stage kidney disease patients is an agreed national priority in Australia. (4, 5, 10) 
7 Inclusion of almost half of the participants from the remote areas meant the findings 
8 from the study is relevant for transplant recipients from rural Australia.
9 Our study extends previous data and records a high morbidity burden, particularly in 
10 the first year after transplantation. This illustrates a critical need to focus on the early 
11 post-transplantation period and examine measures that can reduce hospitalisations, 
12 and in particular infections. This burden of morbidity also manifests itself in long 
13 hospital, and intensive care unit stays in the post-transplant period (particularly in the 
14 first year post-transplant). Falling admission rates in the second year post-
15 transplantation are encouraging and suggest that the longer-term admission rate 
16 should be investigated further in future studies.
17 More than half the kidney transplant recipients in the present study cohort had some 
18 form of biopsy-proven acute rejection episode at least once in the two-year post-
19 transplant period. Day hospital admissions for graft biopsy and ureteric stents 
20 removal add enormous pressure on both the patients and the hospital. Patients are 
21 required to make multiple adjustments to their everyday schedule to attend for the 
22 procedure and post-procedure care. For patients living in remote areas, these 
23 admissions carry the burden of travel to a major centre for hospitalisation. One day-
24 procedure in the regional or tertiary care centre may mean finding someone to 
25 accompany them to their treatment, arriving a day before and leaving a day later 
26 from the city, potentially consuming at least six person-days away from the 
27 community. Some post-transplant encounters occurred at a rural hospital, while 
28 details of these encounters were unavailable because the medical records were 
29 reviewed at a referral centre, this emphasises the importance of ongoing education 
30 of rural hospital staff.  
31 The excess infection rate likely reflects both the underlying rates of infection seen 
32 among the general (non-dialysis) Indigenous population and the effect of 






























































1 immunosuppression. For the general population, the rate ratio for hospitalisation due 
2 to infection in SA and NT between the Indigenous and non-Indigenous from June 
3 2013–2015 was 1·9 and 3·5, respectively. (11) Admission rates were particularly high 
4 among Indigenous Australians living away from major cities. (11) Such areas also 
5 have higher rates of end-stage kidney disease and transplantation. General 
6 measures to reduce the prevalence of infection in remote communities, therefore, 
7 are particularly relevant to this group.
8 There was a close nexus between the high frequency of infection and the burden of 
9 immunosuppression in the first year. The relationships between immunosuppression, 
10 infection and rejection are complex. While cause and effect between these factors 
11 may be difficult to discern in some cases, the data recorded in the present study 
12 suggested that a reduction in immunosuppression due to infection was a major 
13 contributor to the increased rate of rejection.
14 Treatment of BK and CMV viraemia requires a reduction of immunosuppression, 
15 which increases the chance of rejection and graft loss. Current protocols include 
16 valganciclovir prophylaxis for those at high risk of CMV and regular screening for BK 
17 viraemia. At present, there is no established prophylaxis for the prevention of BK 
18 virus infection, which could be considered in high-risk cases. (12) Alternative 
19 approaches, such as ongoing antiviral use for CMV and longer-term or indefinite viral 
20 screening for both CMV and BK virus, should be examined for this group. Further, 
21 differing approaches to organ allocation, such as utilising eplets rather than HLA 
22 matching, may help resolve the underlying issues of immunosuppression vs 
23 infection. (13, 14) Donor BK virus screening may also help stratify high-risk recipients, 
24 though such data are not currently available for Australian donors. (15, 16)
25 The ability to return to the community is a major benefit of transplantation. Previous 
26 studies have highlighted the importance of being able to remain close to family and 
27 stay in the community for Australian Indigenous patients on dialysis. (17) 
28 Transplantation can allow recipients to return to the community and country. 
29 Unfortunately, in the present study, the data available on return to the community 
30 were incomplete. The available data suggested that the majority of patients took 
31 longer than eight weeks to return home. Whether this prolonged interstate stay for 






























































1 transplant surgery discourages patients from opting for transplantation requires 
2 further evaluation.
3 Our study has some limitations. First, the study sample was relatively small, despite 
4 the inclusion of all transplants performed over this period. Data on the treatment of 
5 rejection and the immunosuppressant blood levels were incomplete, though the 
6 proportion of missing data was similar to that of the registry data on the treatment of 
7 rejection. The discharge destination and dates of discharge to the community were 
8 extrapolated from the indirect information available in the hospital records. Follow-up 
9 information confirming participants’ departure to their communities was used to 
10 ensure the accuracy of the dates as best possible. However, it should be noted that 
11 the information on the participants’ return to their referring centres was accurate.
12 Successful transplantation can reduce the burden of remoteness by facilitating the 
13 treatment of people from remote areas in the community. This report identified 
14 several challenges and areas for improvement that can be divided into a) transplant 
15 and person-specific factors and b) general or community-related factors.
16 a) Transplant and person-specific factors include frequent hospital admissions, 
17 extended hospital stay and increased rate of infection, all of which exposed 
18 participants to acute and chronic consequences, such as physical and 
19 emotional stress and increased graft loss in the post-transplant period. Such 
20 factors also meant that participants were away from home for a longer time. 
21 Areas for improvement include broader or prolonged post-transplant 
22 prophylaxis (non-nephrotoxic antifungals, as recommended for lung, liver and 
23 small bowel transplants) for fungal and viral (e.g., a mandatory continuation of 
24 valgancyclovir for one year or more) infections. In cases where repeated 
25 staphylococcus aureus infections occur, decolonisation to reduce the burden 
26 of skin pathogens may be considered, as recommended for the general 
27 population who present with recurrent abscess. (18, 19)
28 Technological advances that reduce the possibility of delayed graft function and 
29 measures that reduce travel time to the transplanting hospital will also help improve 
30 postoperative morbidity and graft outcomes. At present, studies examining the 
31 pharmacodynamics and pharmacokinetics of immunosuppression in Indigenous 
32 Australians to identify appropriate drug dosing protocols, as well as studies exploring 






























































1 epitope matching, are underway. The extent to which an earlier return home is 
2 feasible will vary between people and communities; reducing the high burden of 
3 infection and hospitalisation is an important facilitator of this.
4 b) Community and general factors: in general, improving access to appropriate 
5 housing and health-promotion interventions in the community, including hand 
6 hygiene, are likely to reduce overall community infection rates. (20, 21) Whether 
7 these measures are important from a kidney transplant perspective is yet to 
8 be conclusively shown, but is likely. Improved data-keeping of information 
9 such as time to return the community will allow for the measuring of important 
10 patient-relevant measures such as those outlined above.































































2 Our study demonstrated increased morbidity and mortality in the post-transplant 
3 period, particularly in the first year post-transplantation. Reducing early excess 
4 morbidity after kidney transplantation for these patients is critical, so they can avail 
5 the benefits of this treatment while continuing to live in the country. Management 
6 protocols that aim to reduce the risk of acute rejection, prevent infection in the post-
7 transplant period and enable participants to return home should be prioritised. 
8 Studies exploring the role of broader prophylaxis may help reduce future infections. 
9 Further research is required to explore the inter-relationship between levels of 
10 immunosuppression and the occurrence of infection, and the relationship of these 
11 findings with graft and patient outcomes. It is important to note that, almost half of 
12 the study participants were from remote areas, and the majority were from the NT. 
13 Improvements in provision of dialysis and transplant services in rural and remote 
14 areas mean the number of dialysis and kidney transplant recipients living in these 
15 areas is steadily increasing, and care for this group is becoming an important part of 
16 remote practice.
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Table 1(a): Baseline characteristics of the study participants. 
* IQR- Inter-quartile range ^ RRT- Renal replacement therapy ¶ FEV1- Forced 
expiratory volume in 1 minute, FVC- forced vital capacity
Baseline characteristics of participants Value
N 88
Residential state 37 (42%)
South Australia
Northern Territory 51 (58%)
Remoteness 
Remote/ Very- remote
Areas: South Australia 11%
Remote/ Very- remote
Areas:  Northern Territory 76%
Age at RRT initiation, median (IQR*) 43·5 (35·5, 49)
Gender
Female 39 (44%)
Chronic lung disease at RRT^ start 6 (7%)
Spirometry 
Abnormal- ¶FEV:FVC 60-69% 5 (6%)
Normal- FEV:FVC >=70% 83 (94%)
Coronary artery disease at RRT start 21 (24%)
Coronary Angiography
Normal 18 (20%)
Minor disease 17 (19%)
Abnormal 26 (30%)
Not Performed 20 (23%)
Missing 7 (8%)
Diabetes 
Type 1 or Type 2 53 (60%)
Cerebrovascular disease at RRT^ start 4 (5%)
Peripheral vascular disease at RRT^ start 9 (10%)
Death within 2 years Post-transplant 12 (13·6%)





























































Baseline characteristics of transplants N=89
Donor source- Deceased 89 (100%)
Age at transplant, median (IQR) 47 (41, 55)
Number of first transplant 81 (91·1%)
Donor age, median (IQR) 47 (36, 61)
Donor gender
Female 47 (53%)
Total ischaemia time (hrs), median (IQR) 16·5 (13, 21)
Delayed graft function
Not requiring dialysis 42 (47%)
Delayed Graft Function requiring dialysis 46 (52 %)
Missing information 1 (1%)
Total ischaemia time, categorised
Total ischaemia time <16 hours 40 (44·9%)
Total ischaemia time >16 hours 49 (55·1%)
Initial Immunosuppression
Basiliximab Tacrolimus Mycophenolate Prednisolone 72 (80·9%)
Others including trials and Anti-Thymocyte globulin 17 (19·1%)
Rejection
No rejection 42 (47·2%)
At least one episode of any rejection 47 (52·8%)
Vascular rejection episodes per-participant in 2 years
One episode 22 (24·7%)
2 or more 12 (13·5%)
Cellular rejection episodes per participant in 2 years
One episode 26 (29·2%)
2 or more 19 (21·4%)
Received ATG* for rejection 17 (19·1%)
HLA-A^ mismatch- none 6 (7%)
One HLA mismatch 30 (34%)
Two or more 53 (60%)
HLA-B^ mismatch- none 5 (6%)
One HLA mismatch 16 (18%)
Two or more 68 (76%)
HLA-DR^ mismatch- none 7 (8%)
One HLA mismatch 24 (27%)
Two or more 58 (65%)
HLA-DQ^ mismatch- none 12 (38%)
One HLA mismatch 15 (47%)
Two or more 5 (16%)
Table 1 (b): Characteristics of the kidney transplants. 
*ATG- Anti-thymocyte globulin ^ HLA- Human leucocyte antigen





























































Table 2: Characteristics of the hospital admission for kidney transplant surgery
*Complication: any surgical or medical complication documented as “Yes” in the 
section to mark complication in a discharge summary 
Admission for Transplant Operation Value
N 89
Total inpatient days for transplant surgery, mean (95% CI) days 14 (95% CI, 
10·8-17·2)
Total LOS in ICU during Transplant surgery, median (IQR) 1 (1, 4)
Frequency of total ICU admissions immediate Post-transplant 
period
1 episode of ICU admission 10 (11%)
>1 episode of ICU admission 1 (1%)





Discharge creatinine (excluding dialysis dependant at discharge), 
µmol/l, median (IQR)
224 (122, 490)
Was an infection documented during this admission
Any infection documented 41 (46%)
Type of infection immediate post-transplant (peri-op)
Bacterial 26 (29%)






Miscellaneous- including wound, perfusion fluid, gastrointestinal 
& multiple sites
26 (29%)


































































Total number (N) 89 86 
Inpatient hospital episodes in 2 years 431 779
Hospital admission rate (per person-year) 2·4 (95% CI, 
2·2-2·7)
4·5 (95% CI, 4·2-
4·9)
0·0
Overall rate of admission (per person-year)
up to 1 year 6·8
1-2 year 2·1
Incidence rate ratio for 1: 1-2 year 3·2 (95% CI 2·7-
3·9)
0·0
Day admission 199 (46·2%) 365 (46·9%) 0·8
Total inpatient days per participant in 2 
years, median (IQR)#
6·5 (1·5, 15·5) 14 (5·5, 44·5)
Frequency of Admissions per participant 
in the study period
One or less than one (≤1) 21 (23·6%) 2 (2·3%) 0·0
Two to three (2-3) 25 (28·1%) 13 (5·1%) 0·0
More than three (>3) 43 (48·3%) 71 (82·6%) 0·0
Total LOS in ICU¶ at any time 2 years, 
median (IQR)
2 (1, 4) 7·5 (3·5, 26)
Total ICU¶ admission episodes 13 (0·3%) 23 (2·9%) 0·0
Frequency of ICU¶ admission within each hospital admission episode 
1 13 (100%) 5 (21·7%)
2 6 (26·1%)
3 or more 12 (52·2%)
Proportion of admission episodes where 
an infection was documented 
112 (25·9%) 274 (35·2%) 0·0
Incidence rate of infection (per person-
year)
0·6 (95% CI, 
0·5, 0·8)
1·5 (95% CI, 1·4, 
1·7)
0·0
Discharge destination for each inpatient encounter
Home with or without HITH* 229 (52·2%) 324 (41·3%) 0·0
Hostel 44 (10·0%) 191 (24·3%) 0·0
Other 20 (4·6%) 55 (7·0%) 0·1
Missing 146 (33·3%) 215 (27·4%) 0·0
Table 3: Hospital admission and discharge information in the pre and post-transplant 
period. 
*HITH – Hospital in the home ¶ ICU- Intensive care unit # IQR- Interquartile range
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Figure 1: Mean total length of inpatient stay (in days) in pre and post-transplant period; 
overall length of stay includes day admission during these periods.






























































Figure 2: Time from transplant to the referring hospital 






















































































Figure 3: Details of pre and post-transplant infection









Total admission episodes N=431 N=779
Total number of admission episodes in 2 years 
where Infection was documented 112 (25.9%) 274 (35.2%) 0.0
Incidence rate ratio for admissions with infection in 
the first and second-year post-transplant period 2.5 (95% CI, 1.9, 3.3) 0.0
Infection in the first year post-transplant (of the total 
inpatient episodes in 1st year, n=599) 199 (33.2%) 0.0
Infection in the second year post-transplant (of the 
total inpatient episodes in 2nd year, n=180) 75 (41.7%)
Incidence rate ratio for post and pre-transplant 
hospital admission episodes with infection 2.6 (95% CI 2.1-3.2) 0.0
Type of infection among the episodes where an infection was documented
Bacterial 42 (37.5%) 131 (47.8%) 0.1
Viral 11 (9.8%) 26 (9.5%) 0.9
Fungal 16 (5.8%)
Polymicrobial 44 (16.1%)
Others (including Culture negative) * 59 (52.7%) 57 (20.8%) 0.1
Source of infection
Respiratory 41 (36.6%) 46 (16.8%) 0.0
Gastrointestinal 16 (14.3%) 32 (11.7%) 0.4
AVF-CVC-PD 28 (25%)
Miscellaneous-including skin, urine, multiple sites 37 (24.1%)
Miscellaneous-including skin, multiple sites 82 (29.9%)
Genitourinary 86 (31.4%)
Missing 28 (10.2%)
Infection Episodes in category (out of the total number of admission episodes)
Infection episode=1 23 (5.3%) 21 (2.7%) 0.0
Infection episode >1 89 (20.7%) 253 (32.5%) 0.0
2
3 Table i: Details of pre and post-transplant infection 
4 *includes fungal and polymicrobial infection for the pre-transplant period- categories 
5 combined to improve statistical power. Proportion comparison combined fungal and 
6 polymicrobial with others for the post-transplant period








































































12 Table ii: type of infection in the admission episodes after the escalation of 
13 immunosuppression




Polymicrobial- Bacterial &/or Viral &/or Fungal 17 16.19
Culture negative 34 32.38




Polymicrobial- Bacterial &/or Viral &/or Fungal 17 16.19
Culture negative 34 32.38






























































Total transplant episodes N=89
Pre-transplant Varicella 84 (94%)
Pre-transplant CMV 87 (98%)
Pre-transplant EBV 87 (98%)
Pre-transplant HTLV* 4 (4%)
Pre-transplant HIV (negative) 89 (100%)
Pre-transplant Hepatitis C 4 (4%)
Pre-transplant Hepatitis B 2 (2%)
Pre-transplant Strongyloides* 10 (20%)
Pre-transplant Treponema Pallidum* 15 (29%)
Latent Tuberculosis* 30 (34%)
Toxoplasma 20 (22%)
Table iii: Infection screening  pre-transplant 
*tested in high-risk groups only

































































4.2 A retrospective case-control study exploring factors for loss of kidney 1 
transplant function or death among indigenous kidney transplant recipients 2 
Synopsis: 3 
Survival after kidney transplantation is poor among Australian Aboriginal and Torres 4 
Strait Islanders (hereafter referred to as Indigenous Australians) when compared to 5 
non-indigenous kidney transplant recipients(12). When compared to their non-6 
indigenous counterparts, deaths due to infectious diseases were substantially higher 7 
among Indigenous kidney transplant recipients in all of Australia (99).   8 
A retrospective case-control study was conducted, to identify risk factors for graft 9 
and patient survival among Indigenous kidney transplant recipients, beyond the 10 
information available from the Australia and New Zealand Dialysis and Transplant 11 
(ANZDATA) Registry.  12 
Methods 13 
Cases were defined as all Australian Indigenous kidney transplant recipients from 1st 14 
January 2005 to 31 December 2015 from the major hospitals in the Northern 15 
Territory (NT) and South Australia (SA) who experienced graft loss (including patient 16 
death) up to 2 years post-transplant. Controls (matched 4:1) were defined as all 17 
Indigenous kidney transplant recipients during the same period, from same locations 18 
with functioning kidney transplant at two years post-transplant operation. Matching 19 
was done on gender and presence or absence of diabetes status. The analysis was 20 
adjusted for age at kidney replacement therapy (KRT) start. Hospital-level data was 21 





cases and controls. Post-transplant hospital admission rate excluded day admissions 1 
such as admissions for transplant biopsy and ureteric stent removal. 2 
Results 3 
There were 17 cases and 68 matched controls. Among the cases, odds ratio (OR) 4 
for more than one hospital admission episode (compared to ≤1 episode) in the two 5 
years pre-transplant period was 6.2 (95% CI, 1.2- 32.5). However, there were no 6 
significant differences in the frequency of comorbidities at KRT start, cardiovascular 7 
intervention pre-transplant, pre-transplant infection screening, age and gender of the 8 
donors, frequency of admission episodes where an infection was documented, the 9 
total length of inpatient stay or admission to intensive care unit (ICU) during pre-10 
transplant hospital admission between cases and controls.    11 
Conclusion: 12 
Early loss of graft was predicted by a higher frequency of hospital admissions in the 13 
two-year pre-transplant period. In contrast, other measured factors in the pre-14 
transplant period did not predict these adverse outcomes. 15 
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1 A retrospective case-control study exploring pre-transplant predictors for loss of 
2 kidney transplant function or death among Indigenous kidney transplant recipients 




7 A retrospective case-control study was conducted, to identify risk factors for loss of 
8 kidney transplant function or death among the Indigenous kidney transplant 
9 recipients.
10 Methods
11 Cases were defined as all Australian Indigenous kidney transplant recipients from 
12 1st January 2005 to 31 December 2015 from the major hospitals in the Northern 
13 Territory (NT) and South Australia (SA) who experienced graft loss (including patient 
14 death) up to 2 years post-transplant. Controls (matched 4:1) were defined as all 
15 Indigenous kidney transplant recipients during the same period with functioning 
16 transplants at two-years post-transplant operation. Matching was done on gender 
17 and diabetes status. Regression analysis adjusted for age was used for comparing 
18 cases and controls.































































2 There were 17 cases and 68 matched controls. Among cases, odds ratio (OR) for 
3 more than one hospital admission episode (compared to ≤1 episode) in the two 
4 years pre-transplant period was 6.2 (95% CI, 1.2- 32.5). However, there were no 
5 significant differences in other measured comorbidities between cases and 
6 controls.   
7 Conclusion 
8 Early loss of graft was predicted by a higher frequency of hospital admissions in the 
9 two-year pre-transplant period. Furthermore, broader social determinants of health 
10 should be addressed in order to improve pre-transplant health and thus improve the 
11 potential for optimal post-transplant outcomes.
12 Keywords: Kidney allograft function/dysfunction, graft survival, ethnicity, complication, 
13 clinical decision-making































































2 For the majority of people with end-stage kidney disease (ESKD); when compared to 
3 dialysis, kidney transplantation offers an advantage in survival and cost. Transplant 
4 recipients can also expect a better quality of life. (1, 2) Nevertheless, the rate of kidney 
5 transplantation among Australian Indigenous end stage kidney disease (ESKD) 
6 patients is substantially lower, and differences persist in graft and patient survival. (3-
7 5) The majority of deaths among kidney transplant recipients are due to 
8 cardiovascular diseases, cancer and infectious diseases(6). Higher rates of deaths 
9 due to infection may explain decreased rates of graft and patient survival in the 
10 Indigenous kidney transplant recipients; with the risk highest from 6 to 24 months 
11 post-transplantation. (7) Previous studies have utilised information drawn from the 
12 Registry data. (3, 4, 7) However, the registry data is limited in providing information on 
13 specific clinical factors at the patient and hospital levels. The association between 
14 reasons for hospital admission pre-transplant, types of infection in cases of infection-
15 related admissions, the severity of illness,  length of hospital stay, discharge 
16 destination, the severity of comorbidities, and patient or graft survival are not known. 
17 In this study, we aim to identify the pre-transplant risk factors for early graft loss and 
18 death among Indigenous kidney transplant recipients. To explore the predictors of 
19 this outcome, we conducted a retrospective case-control study to examine possible 
20 risk factors. 































































2 Study population and data source:  Australian Indigenous kidney transplant 
3 recipients from 1st January 2005 to 31st December 2015 from the major hospitals in 
4 the Northern Territory (NT, Alice Springs Hospital and Royal Darwin Hospital) and 
5 South Australia (Central and North Adelaide Renal Transplantation Services and 
6 Flinders Medical Centre) were identified from the ANZDATA Registry.  At each 
7 hospital, medical records for these participants were audited. Information was 
8 collected on the dates of admission and discharge, frequencies of hospital 
9 admissions, the reason for each admission as documented in the discharge 
10 summary or from the progress notes where such a summary was missing, laboratory 
11 and radiologic investigations, pre-transplant screening investigation results, and 
12 details of pre-transplant cardiovascular intervention. Information was obtained for the 
13 two years pre-transplant on the included participants. Hospital-based electronic and 
14 hard copies of the medical records were reviewed. Where the data was missing from 
15 the hospital records, then the data from the ANZDATA registry was utilised if 
16 available.  
17  Cases were selected from the cohort of included participants (described above) and 
18 defined as those who sustained graft loss (includes graft failure- defined as the 
19 return to long-term dialysis and patient death) within two-years post-transplant. 
20 Controls were also selected from the same cohort of included participants and 
21 defined as those who had a functioning graft at two-years post-transplant. Matching 
22 was performed on analysis time (the time from transplantation to the graft failure or 
23 death), gender and presence or absence of diabetes. Matching on age band was 
24 attempted; however, it was not possible within the cohort. As recommended, we 
25 adjusted for the covariates used in case-control matching in the analysis. (8) 






























































1 Hospital encounters for maintenance haemodialysis were excluded from the 
2 calculation of hospital admission rates. Infection episode was defined as the episode 
3 of hospital admission in which any infection was documented during that admission 
4 by investigation results or was given an infection-related diagnosis by the treating 
5 team. Coronary angiogram results were categorised based on the cardiologists’ 
6 interpretation provided on the report. An angiogram result was categorised abnormal 
7 if the report mentioned the involvement of “any” number of coronary arteries and was 
8 reported other than “a minor disease”. Remoteness was determined using the 
9 postcode of residence in the patient records linked to the postcode concordance 
10 available from the Australian Bureau of Statistics (ABS). (9) 
11 Statistical analysis: Analyses were performed using Stata Tx version 15. For the 
12 analysis carried out for this study, there were a set of 4 controls per case with 
13 matched analysis time, gender and diabetes status. Regression analysis was 
14 adjusted for age at renal replacement therapy (RRT) initiation to account for the 
15 inability to include matching on age band. Conditional logistic regression was used to 
16 generate odds ratio (OR) adjusted for age. For comparison of hospital admission 
17 rates, multilevel Poisson regression was used as a paired analysis to account for the 
18 random effect of each set of cases and controls. The Incidence rate and incidence 
19 rate ratio is presented for the pre-transplant hospital admission rate for the cases 
20 and controls. Mean of covariates was compared using pairwise mean comparison, 
21 and the OR was calculated using conditional logistic regression. Wilcoxon’s signed-
22 rank test and Pearson’s χ2 were used for comparison of baseline characteristics. P-
23 value of <0.05 was considered statistically significant. Data were analysed using 
24 Stata 15 statistical software.
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2 There were 89 transplant operations among 88 Indigenous kidney transplant 
3 recipients who met the inclusion criteria during the study period. There were 17 
4 cases, and 68 matched controls were randomly selected (1:4).
5 Baseline characteristics:
6 Table 1 shows the baseline characteristics, including the pre-transplant screening 
7 tests of the cases and controls. No difference in the proportion of participants from 
8 the SA and NT between the cases and controls was found. No difference was found 
9 between the two groups. No difference in the remoteness categories or the presence 
10 of comorbidities (reported at the RRT start) was seen between the cases and 
11 controls. The OR for remote compared to non-remote was 2.0 (95% CI, 0.7, 6.1). 
12 The OR for the comorbidities is presented in Table 2. 
13 Transplant specific information (Table 3):
14 All of the transplants were from deceased donors. The median age of donor among 
15 the cases was higher (52 vs. 45 years). However, the difference was not statistically 
16 significant. There was no significant difference in the distribution of HLA mismatch 
17 between the cases and controls. Table 4 shows the OR for HLA between cases and 
18 the controls.
19 Pre-transplant hospital admissions:
20 The hospital admission rate in the two-year pre-transplant period (excluding hospital 
21 encounter for maintenance dialysis) was 3.2 per-person years among the cases and 
22 1.6 per-person years among the controls. The overall rate ratio (RR) of pre-
23 transplant hospital admission for cases vs controls was 1.7 (95% CI, 1.3, 2.1). In the 






























































1 12 months before the transplant, the RR for hospital admission was 1.9 per person-
2 year (95% CI, 1.4, 2.7) for cases vs. controls and 1.4 per person-year (95% CI, 0.9, 
3 1.9) in 13 to 24 months period pre-transplant. No difference in the rate of ICU 
4 admission was found between the cases and controls in the two-year pre-transplant 
5 period, IRR 1.2 per person (95% CI, 0.2, 5.9). The pre-transplant mean length of 
6 stay was similar between the cases and controls 11.9 vs. 8.9 days, respectively.
7 Admission episodes where an infection was documented:
8 The rate of admission where infections were documented in the pre-transplant period 
9 was 0.6 episodes per-person year among cases and 0.5 episodes per-person year 
10 among controls. RR between cases and control for episodes where an infection was 
11 documented was 0.9 (95% CI, 0.6, 1.6). Appendix table i shows the type of infection 
12 documented during the admissions.
13  































































2 There are persistent disparities in survival after kidney transplantation for Indigenous 
3 Australians, (10) with a particular increase in graft loss in the first two years. Infectious 
4 diseases related deaths are substantially higher among Indigenous kidney transplant 
5 recipients. (11)  
6 Understanding the predictors of these adverse events is critical to improving these 
7 outcomes. To evaluate this, we examined cases (all Australian Indigenous kidney 
8 transplant recipients from 1st January 2005 to 31 December 2015 from major 
9 hospitals in the NT and South Australia (SA) who returned to dialysis or died in the 
10 period up to two-years post-transplant). We compared these to controls (matched 
11 Indigenous kidney transplant recipients from 1st January 2005 to 31 December 2015 
12 from major hospitals in the NT and SA who had a functioning kidney transplant at 
13 two-years post-transplant). This is the first time pre-transplant predictors have been 
14 examined in detail among Australian Indigenous transplant recipients. We found that 
15 the cases had a higher rate of hospital admission in the two-year pre-transplant 
16 period, and an increased frequency of pre-transplant hospital admissions as 
17 compared to their matched controls. 
18 We did not find a difference between the cases and controls in other factors; length 
19 of hospital stay, remoteness, comorbidities at the start of RRT, pre-transplant 
20 screening tests (for infection or cardiovascular disease), pre-transplant 
21 cardiovascular intervention, and HLA mismatch.  
22 There is a paucity of data on the effect of pre-transplant morbidities like hospital 
23 admission and relationship to kidney transplant outcome. Our findings match the 
24 observation made by Lynch et al. (12) They examined the impact of hospitalisation 






























































1 among waitlisted patients from the United States Renal Data System (and the first 
2 year of waitlisting). They reported decreased graft and patient survival among the 
3 patients who had higher admissions in the pre-transplant period; however, the 
4 survival benefit was preserved among their study participants. In a separate study, 
5 Lynch et al. (13) reported that age at RRT initiation, gender, comorbidities except for 
6 diabetes, and sensitisation did not predict transplant outcomes. However, 
7 hospitalisations in the year before transplantation and length of hospital stay were 
8 significantly associated with graft loss and patient death. In contrary to their finding, 
9 length of hospital stay was not a predictor of graft loss in our study. 
10 Based on our study findings, we propose that to improve kidney transplant outcomes 
11 in the Indigenous Australians, specifically in the first two-year post-transplant, it is 
12 essential to act in the pre-transplant period. Efforts to reduce pre-transplant hospital 
13 admissions may be helpful. This might include and not be limited to the identification 
14 of reasons for admissions and development of strategies to prevent such conditions 
15 where possible.  Increased hospitalisations in the pre-transplant period could be a 
16 reflection of overall higher admission among the Indigenous Australians. (14) 
17 Therefore general measures at the community level to improve health among 
18 Indigenous Australians may help.  Future studies should consider examination of 
19 other factors like the effect of severity of comorbidities and dialysis vintage on the 
20 transplant outcomes. While better HLA matching could be argued as a logical way to 
21 improve graft outcome, in practice, this will cause significant delay for the Indigenous 
22 Australians in receiving a kidney transplant. Based on their findings, Molnar et al. 
23 developed a post-transplant outcome prediction tool using the data available before 
24 the time of transplantation. this tool performed better for ESKD patients in the United 
25 States in predicting graft survival than existing prediction tools like Estimated Post-






























































1 Transplant Survival score. (15) Consideration may be given to the development of 
2 similar tools specific for Australian Indigenous kidney transplant recipients.
3 Our study is not without limitations. The sample size was small; however, case-
4 control study methodology is statistically robust for identification of factors that may 
5 be associated with a rare outcome such as graft loss which involves a latency period 
6 for the outcome to occur. The small sample size is intrinsic to the study group and 
7 persisted despite the inclusion of all Indigenous transplant recipients during the study 
8 period. Optimal matching of cases and controls and using age adjustment in the 
9 regression analysis prevented overmatching and introduction of bias. (16) Our cohort 
10 included Indigenous Australians with ESKD in South Australia and the Northern 
11 Territory; hence the findings may not be generalisable to other jurisdiction in 
12 Australia. Finally, due to the nature of data collection, i.e. review of medical records; 
13 data for some covariates were missing (e.g. due to absence of discharge 
14 summaries, sheets with incomplete details for emergency department encounters 
15 and in some cases some volumes of the records were not available for review). 































































2 Our findings suggest that there is an increased rate of pre-transplant hospital 
3 admission amongst Indigenous Australians who experience early graft loss. Other 
4 factors such as remoteness, comorbidities at the start of RRT, pre-transplant 
5 screening tests, and HLA mismatch were not associated with poor outcomes. Efforts 
6 to reduce pre-transplant hospital admission rates and the burden of infection may be 
7 helpful. Future studies might need to explore other issues specific to ESKD patients, 
8 such as the severity of comorbidities, iron stores, phosphate and parathyroid 
9 hormone levels, and consideration might be given to the development of outcome 
10 prediction tool specific for Indigenous patients. Improvement in record-keeping is 
11 also essential to improve the quality of data for studies like ours and thus our ability 
12 to understand key predictors for transplant outcomes. Furthermore, broader social 
13 determinants of health should be addressed in order to improve pre-transplant health 
14 and thus improve both access to transplant and potential for optimal post-transplant 
15 outcomes. 
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Covariates Attributes Controls (n=68) Cases (n=17)
Residential state South Australia 20 (39%) 6 (35%)
Northern Territory 48 (71%) 11 (65%)
Remoteness 
categories
Remote 28 (41%) 10 (59%)
Age at RRT¶ 
initiation, median 
(IQR∞)
42 (33, 48.5) 44 (36, 47)




10 (15%) 0 (0%)
Coronary artery 
disease at RRT¶ 
start
Yes 21 (31%) 1 (6%)
Coronary 
Angiography
Normal 16 (24%) 5 (29%)
Minor disease 18 (26%) 2 (12%)
Abnormal 17 (25%) 5 (29%)
Not Performed 14 (21%) 2 (12%)





Yes 7 (10%) 2 (12%)
Chronic lung 
disease at RRT¶ 
start





7 (10%) 0 (0%)
Cerebrovascular 
disease at RRT¶ 
start
Yes 3 (4%) 0 (0%)
Peripheral vascular 
disease at RRT¶ 
start
Yes 7 (10%) 3 (18%)
Mantoux Test LTBI* 31 (46%) 7 (41%)
Not indicated 33 (49%) 10 (59%)
Missing 4 (6%) 0 (0%)
Varicella 
serology
Positive 65 (96%) 16 (94%)
Missing 0 (0%) 1 (6%)
Cytomegalovirus 
serology 
Positive 68 (100%) 17 (100%)
Epstein-Barr Virus 
serology
Positive 66 (97%) 16 (94%)
Strongyloides Equivocal 1 (2%) 0 (0%)
Positive 8 (18%) 2 (18%)
































































Positive 11 (23%) 4 (36%)
Meliod Positive 4 (13%) 0 (0%)
Toxoplasma Positive 18 (26%) 3 (18%)








No 68 (100%) 17 (100%)
Hepatitis C Positive 4 (6%) 1 (6%)
Hepatitis B Positive 1 (1%) 0 (0%)
Table 1: Baseline characteristics of the cases and controls– showing comorbidities at 
the renal replacement therapy (RRT) start, and pre-transplant screening test results. 
¶ RRT- Renal replacement therapy ∞ IQR- Interquartile range € CABG- Coronary 
artery bypass graft *LTBI- Latent tuberculosis infection ¥FEV: FVC- Forced expiratory 
volume: Forced vital capacity ratio 
Comorbidities




Chronic lung disease 3.4 (0.5, 22.1) 0.2
Coronary artery disease 0.1 (0.0, 1.0) 0.1
Peripheral vascular 
disease
1.8 (0.4, 7.9) 0.4
Table 2: Odds Ratio for the comorbidities, reported at the renal replacement therapy 
(RRT) start. Adjusted for age at RRT initiation






























































Covariates Attributes Controls (n=68) Cases (n=17)
Age at transplant, 
median (IQR*)
47 (38, 53) 48 (43, 52)
Donor age, median 
(IQR)
45 (34.5, 58.5) 52 (46, 61)
Donor gender Female 36 (53%) 11 (65%)
Male 32 (47%) 6 (35%)
Donor source Deceased 68 (100%) 17 (100%)
HLA-A¶ mismatch 0 2 (3%) 1 (6%)
1 23 (34%) 6 (35%)
2 43 (63%) 10 (59%)
HLA-B¶ mismatch 0 1 (1%) 1 (6%)
1 13 (19%) 2 (12%)
2 54 (79%) 14 (82%)
HLA-DR¶ mismatch 0 5 (7%) 1 (6%)
1 17 (25%) 4 (24%)
2 46 (68%) 12 (71%)
HLA-DQ¶ mismatch 0 13 (59%) 2 (40%)
1 8 (36%) 3 (60%)
2 1 (5%) 0 (0%)
Table 3: Transplant specific information * IQR- Interquartile range ¶ HLA- Human 
leucocyte antigen































































Odds ratio (OR) for Cases 
compared to controls (95% 
Confidence Interval)
Total length of stay
Mean difference between 
cases and controls 2.9 
days (95% CI, -4.7, 10.6)
1 (95% CI, 0.9, 1)
Admission frequency 
compared to ≤1 episode
> 1 episode 6.2 (95% CI, 1.2- 32.5)
Admission with infection
IRR¶ of admissions where 
an infection was 
documented
0.9 (95% CI, 0.6, 1.6)
HLA-A 
compared to two or more 
mismatch
0.8 (95% CI, 0.3-2.4)
HLA-B
compared to two or more 
mismatch
1.3 (95% CI, 0.3-5.1)
HLA-DR
compared to two or more 
mismatch
1.1 (95% CI, 0.3-3.6)
Table 4: Showing Odds ratio (OR) for cases as compared to controls in the pre-
transplant period, Adjusted for age at RRT initiation and IRR for admission episode 
where an infection was documented
*ICU- Intensive care unit, ¶IRR- Incidence rate ratio






























































Type of infection in the pre-transplant period Controls Cases 
Bacterial 35 (15.2) 5 (4.6)
Viral 5 (3.0) 7 (6.5)
Others including culture negative 38 (16.5) 10 (9.3)
Not infection 151 (65.4) 86 (79.6)
Appendix 1: Type of infection in the admission episodes where an infection was 
documented in the 2-year pre-transplant period











































































In this thesis, I sought to identify factors which are associated with access to the 1 
waiting list and outcomes of kidney transplantation for Indigenous Australians with 2 
ESKD.  Our research has added to previous work (14, 75, 83) through utilising 3 
updated and recent waiting list information and bringing together hospital derived 4 
data with registry information to more comprehensively explore the individual factors 5 
associated with the examined outcome measures.  6 
Firstly, the current trend of kidney replacement therapy (KRT) distribution among 7 
Indigenous patients with ESKD was explored, and comparisons made to non-8 
indigenous patients. In this study, we confirmed the much higher prevalence of 9 
facility-based haemodialysis among Indigenous Australians. (50) 10 
In chapter two, we showed that the likelihood of placement on the transplant waiting 11 
list for kidney transplantation was reduced for Indigenous Australians compared to 12 
non-indigenous Australians. Also, the time taken to be placed on the waiting list was 13 
longer than for their non-indigenous counterparts. (77)  “Delays in being accepted for 14 
the waiting list consequently lead to patients being near the top of the list at the time 15 
of listing, increasing their likelihood of transplantation soon after listing. This is 16 
reflected in the shorter median time to transplantation after placement on the 17 
transplant waiting list and higher rates of transplantation in the first year after 18 
placement on the waiting list, after which the transplantation rate falls.” (77) The 19 
factors contributing to the remaining gap in accessing waiting list and kidney 20 
transplantation among Indigenous Australians with ESKD are yet to be identified and 21 
addressed. Some of the factors contributing to the gap could be due to lack of clear 22 
understanding of the transplant process and cultural and language barriers as was 23 





(IMPAKT) project. (10, 97, 98) That study also identified systemic issues as 1 
additional barriers affecting access to transplantation.  2 
The process of kidney transplantation has been described as difficult and confusing. 3 
The development of a culturally appropriate system that supports Indigenous 4 
patients, their families, and clinicians with knowledge of specific cultural needs will 5 
be helpful. (100)  Participants interviewed in that study demonstrated their interest in 6 
receiving a kidney transplant. They demonstrated that their understanding of kidney 7 
transplant as the only way to improve quality of life, which allows them to live in the 8 
community, unlike dialysis, which requires relocation and makes spending time with 9 
family and friends possible. They viewed dialysis as an isolating form of treatment.  10 
(100) 11 
The literature, and our study, consistently indicate that remoteness is a key factor in 12 
access to the waiting list and kidney transplantation among Indigenous Australians 13 
with ESKD. (15, 77, 79, 96, 100-103) The term “remoteness” can be associated with 14 
multiple factors that impact access to health care (2) including access to kidney care 15 
(e.g. lack of access to specialised services like the pathology services required for a 16 
kidney transplant, and the need to travel long distances to be assessed for transplant 17 
eligibility to name a few), (15, 71, 79) all of which put people from these areas at a 18 
major disadvantage. This emphasises the need for making these services available 19 
closer to the remote communities in which patients live.  20 
Despite the use of advanced statistical methods to adjust for the effect of 21 
remoteness and other measured factors in our study, the gap in the rates of 22 
placement on transplant waiting list between Indigenous and non-indigenous 23 





qualitative and mixed-method studies to examine patients’ perspectives and to 1 
understand the factors at the patient level that have a real-world impact on 2 
placement on transplant waiting list/transplant opportunities.  3 
The findings from our study, (77) attracted significant media and national attention. 4 
Together with observations from other researchers, (15, 89, 100, 101) this led to the 5 
establishment of the National Indigenous Kidney Transplantation Taskforce (NIKTT) 6 
in 2018. (85) Our study informed the NIKTT’s advocacy for equitable access to 7 
transplantation for Indigenous Australians with ESKD.  8 
Chapter three examined another specific individual-level factor – attendance at 9 
facility haemodialysis. This was examined in an NT-based ESKD cohort. Inability to 10 
adhere with the complex medical therapy, particularly with respect to the transplant 11 
immunosuppression, is one of the general conditions set out as exclusion criteria for 12 
transplantation. (86, 104) Specific guidelines to identify patients at high risk of non-13 
adherence post-transplantation do not exist. Dialysis attendance is often used as a 14 
marker of compliance to the medical treatment and is likely to form an important 15 
factor in the transplant assessment process at an informal level. (86) A national 16 
survey conducted in 2007 raised concerns that the nephrologists’ decision to refer or 17 
not refer a patient for placement on the transplant waiting list and kidney 18 
transplantation was influenced by a patient’s adherence to dialysis treatment. (83)  19 
We showed a reduced chance of transplantation (placement on the transplant 20 
waiting list) among participants with ≤2.5 sessions/week dialysis attendance, and no 21 
participants with dialysis attendance in the lowest quintile received a kidney 22 
transplant. Nevertheless, there was no association found between dialysis 23 





Although it included all transplants over 16 years, the number of people waitlisted for 1 
transplantation was very low—this limited the power of statistical analyses.  2 
Furthermore, our findings highlight the need to understand the reasons behind 3 
reduced attendance, which can come from gaining patients’ perspectives and review 4 
of the health system factors which may be associated with these issues. The 5 
relevance of these reasons post-transplantation is not yet known. Frequently, 6 
Indigenous patients have voiced the need for availability of dialysis closer to home in 7 
the remote community, and dialysis attendance may improve with this change. (79) 8 
Given that, the remote Australian communities are widely distributed over a big 9 
landmass, the development of sustainable infrastructure is extremely difficult. When 10 
the number of people accessing the waiting list and receiving a kidney transplant 11 
increases, the effect of dialysis attendance on kidney transplant outcomes may be 12 
explored again. Mixed-method studies and examination of recent data might allow 13 
further understanding of other factors that affect attendance, placement on the 14 
transplant waiting list and transplantation.  15 
Finally, two projects (described in chapter 4.1 and 4.2) were designed to identify 16 
factors associated with graft loss (including patient death). Both studies were 17 
conducted in the cohort of Indigenous kidney transplant recipients from 2005 to 18 
2015.   19 
The descriptive cohort study (described in chapter 4.1, pages 84-111) identified the 20 
morbidity burden among Indigenous kidney transplant recipients in the pre- and post-21 
transplant period.  We found that there was an increased burden of hospitalisation in 22 
the post-transplant period. This burden was higher in the first year post-23 





development of evidence-based management protocols to help reduce the rates of 1 
hospitalisation, infections, length of inpatient stay, and the severity of illness during 2 
these episodes should be considered and focused on issues in the first-year post-3 
transplantation.  Because rates of infection in the post-transplant hospital admission 4 
were higher in our study population, we suggest that consideration should be given 5 
to modification of existing anti-infective prophylaxis (e.g. lengthen the duration of 6 
antiviral prophylaxis) protocols in the post-transplant period.  7 
Fifty per cent of our study population suffered from delayed graft function (DGF), and  8 
55% of the study population had a total ischaemia time of >16 hours. DGF is 9 
associated with poor graft outcomes,  (105)  and reduction in cold ischaemia time is 10 
associated with a lower incidence of DGF. (15, 106)  Measures to reduce the cold 11 
ischaemia time by addressing issues associated with the transfer of participants to 12 
the transplanting centres may be useful in reducing the frequency of such adverse 13 
events in our study population. It is important to note that almost 50% of our study 14 
population were residents of the NT. The NT ESKD patients undergo kidney 15 
transplants in South Australia (SA) and must fly to the transplanting hospital upon 16 
acceptance of the organ offered. For a potential recipient who resides in the remote 17 
and very remote areas of the NT, it takes several hours to access the nearest airport 18 
leading to significant time lag to reach the transplanting hospital in SA. New methods 19 
of organ preservation may reduce the impact of long cold ischaemia time and hence 20 
reduce one of the hurdles associated with remoteness.  21 
Furthermore, community-level efforts to reduce overall infection and hospital 22 





In the study described in chapter 4.2 (pages 114-137), a retrospective comparison of 1 
cases with matched controls (1:4) selected from an above cohort of Indigenous 2 
transplant recipients (included in the study described in chapter 4.1), was performed. 3 
Besides increased rates of hospitalisation in the pre-transplant period, other factors 4 
examined (length of hospital stay, remoteness, comorbidities at the start of KRT, pre-5 
transplant screening tests (for infection or cardiovascular disease), pre-transplant 6 
cardiovascular intervention, and HLA mismatch) did not show a causal relationship 7 
with graft loss within the two-year post-transplant period. While this is not an 8 
uncommon finding in other parts of the world, (107, 108) this is the first time such an 9 
observation has been made among Indigenous Australian kidney transplant 10 
recipients. The reasons for increased hospitalisation may be specific to ESKD or 11 
more general issues which drive hospitalisation rates of non-dialysis Indigenous 12 
Australians from remote areas. (2) 13 
Other areas for further investigation include identification of reasons for admissions 14 
and development of strategies to prevent such conditions where possible to reduce 15 





Conclusion   1 
Our study confirmed the high prevalence of facility-based haemodialysis among 2 
Indigenous Australians with ESKD. This high prevalence translates into potential 3 
barriers to regular attendance and utilisation of dialysis services and possibly a need 4 
for relocation to improve access to kidney care. While alternative treatments at home 5 
are possible, there are significant challenges to make this a sustainable solution. In 6 
such circumstances, kidney transplant appears a suitable option to enable 7 
Indigenous Australians to receive treatment closer to their home and community. 8 
However, we found that Indigenous Australians with ESKD had significantly lower 9 
chances of placement on the transplant waiting list and transplantation. Existing 10 
research and our study suggest that understanding the multitude of factors 11 
associated with health and patterns of health service utilisation in remote 12 
communities might provide a broader knowledge base to better assist healthcare 13 
providers in making decisions that impact Indigenous patient care.  14 
The critical findings of our study show that less than 2% of Indigenous patients in our 15 
cohort receiving KRT were waitlisted for a deceased donor kidney transplant. Our 16 
study found no correlation between dialysis attendance and transplant outcomes, 17 
although this is a factor that influences nephrologists’ decisions to refer patients for 18 
transplant assessment and transplantation. Raising awareness and initiation/ 19 
reinforcement of education when one is at a relatively earlier stage of CKD may help. 20 
Measures to perform most of the transplant workup closer to the dialysis unit, and 21 
hence closer to a patient’s home, might reduce the need for recurrent travel and may 22 
improve attendance at transplant centres for the pre-transplant tests which cannot be 23 
performed elsewhere. Utilisation of existing Indigenous transplant recipients in the 24 





also be helpful by reducing the communication gap when using the non-indigenous 1 
educators. Supporting the development of consumer representative groups to be the 2 
voice of these patients, and ensuring consumer consultation in the development of 3 
management protocols should be considered.   4 
Additionally, we showed the need for better understanding of the reasons for 5 
frequent hospitalisation. Strategies to prevent widespread infection (including 6 
reinforcement of hygiene measures, newer solutions for over-crowding) and 7 
programs from raising infection awareness may be helpful.  Measures to reduce 8 
delayed graft function by reduction of cold ischaemia time may also be helpful. 9 
Development of better immunosuppression protocols taking into consideration 10 
pharmacokinetic and pharmacodynamic differences, tailored to Indigenous 11 
transplant patients, may help reduce some of the infections in the post-transplant 12 
period.  13 
One of the key steps in transplantation is the final step of organ allocation to the 14 
potential patient on the transplant waiting list. Organ allocation is based on following 15 
criteria set out by Transplant Society of Australia and New Zealand: Blood group 16 
compatible (e.g. A to A) and blood group acceptable (e.g. O to B); waiting time; HLA 17 
matching (tissue typing to determine the level of immunological compatibility 18 
between a donor and recipient); HLA-antibody detection (which can identify 19 
unacceptable HLA antigens, and be used to preclude certain donors); certain priority 20 
allocations (e.g. paediatric recipients defined as age <18 years, combined organ 21 
recipients such as kidney-pancreas, highly sensitised recipients); and the 22 
requirement to maintain an equitable flow of kidneys between states and territories. 23 
This algorithm is set to balance parity across transplant jurisdictions, equity and 24 





demerit their chance of transplantation. Whether remoteness impacts patients’ 1 
decision to receive a marginal kidney or their nephrologists’ decision to accept such 2 
a kidney is unknown. Also, whether a change in the current allocation process to 3 
eplets matching be beneficial for Indigenous Australians with ESKD remains unclear- 4 
an aspect that deserves further exploration. Despite an extensive search, the data 5 
on when and whether the transplant recipients were able to return to their community 6 
post-transplant was incomplete in our study. Improved record keeping will help 7 
outline the journey of the transplant recipients and help identify other barriers to be 8 
overcome.  9 
Furthermore, we found that the only factor in the pre-transplant period, which 10 
predicted early graft-loss among Indigenous transplant recipients was increased 11 
rates of pre-transplant hospitalisation. A better understanding of the underlying 12 
reasons for hospitalisations among Indigenous Australians with ESKD, and 13 
measures to reduce these events, should be prioritised. Finally, more studies to 14 
identify other factors which play a role in determining access to the waiting list, 15 
kidney transplantation and improving transplant outcomes among Indigenous 16 
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